Effect of DNA repair deficiencies on the cytotoxicity of drugs used in cancer therapy-A review

Current Medicinal Chemistry

Volumn 21, Issue 30, 2014, Pages 3419-3454

  Calderón Montaño, José Manuel ^a   Burgos Morón, Estefanía ^a   Orta, Manuel Luis ^a   López Lázaro, Miguel ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Anticancer; Chemotherapy; DNA damage; DNA damage response

Indexed keywords

ALKYLATING AGENT; ANTIBIOTIC AGENT; ANTIMETABOLITE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE INHIBITOR; FANCONI ANEMIA PROTEIN; ANTIINFECTIVE AGENT; DNA (CYTOSINE 5) METHYLTRANSFERASE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; DNA DAMAGE; DNA END JOINING REPAIR; DNA REPAIR; DRUG CYTOTOXICITY; DRUG TARGETING; EXCISION REPAIR; HOMOLOGOUS RECOMBINATION; HUMAN; MISMATCH REPAIR; DRUG EFFECTS; METABOLISM; NEOPLASMS;

ALKYLATING AGENTS; ANTI-BACTERIAL AGENTS; ANTIMETABOLITES; ANTINEOPLASTIC AGENTS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA REPAIR; HUMANS; NEOPLASMS; TOPOISOMERASE INHIBITORS;

EID: 84919944457     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140601203816     Document Type: Article

References (416)

1. Lord, C.J.; Ashworth, A. The DNA damage response and cancer therapy. Nature, 2012, 481, 287-294
2. Basu, B.; Yap, T.A.; Molife, L.R.; de Bono, J.S. Targeting the DNA damage response in oncology: past, present and future perspectives. Curr. Opin. Oncol., 2012, 24, 316-324
3. Jackson, S.P.; Bartek, J. The DNA-damage response in human biology and disease. Nature. 2009, 461, 1071-1078
4. Vasen, H.F.; Moslein, G.; Alonso, A.; Bernstein, I.; Bertario, L.; Blanco, I.; Burn, J.; Capella, G.; Engel, C.; Frayling, I.; Friedl, W.; Hes, F.J.; Hodgson, S.; Mecklin, J.P.; Moller, P.; Nagengast, F.; Parc, Y.; Renkonen-Sinisalo, L.; Sampson, J.R.; Stormorken, A.; Wijnen, J. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J. Med. Genet., 2007, 44, 353-362
5. Christmann, M.; Tomicic, M.T.; Roos, W.P.; Kaina, B. Mechanisms of human DNA repair: an update. Toxicology, 2003, 193, 3-34
6. Hoeijmakers, J.H. Genome maintenance mechanisms are critical for preventing cancer as well as other aging-Associated diseases. Mech. Ageing Dev., 2007, 128, 460-462
7. Larizza, L.; Roversi, G.; Volpi, L. Rothmund-Thomson syndrome. Orphanet. J. Rare Dis., 2010, 5, 2
8. Curtin, N.J. DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. Cancer, 2012, 12, 801-817
9. Jenkins, C.; Kan, J.; Hoatlin, M.E. Targeting the fanconi anemia pathway to identify tailored anticancer therapeutics. Anemia, 2012, 2012:481583
10. Joenje, H.; Patel, K.J. The emerging genetic and molecular basis of Fanconi anaemia. Nat. Rev. Genet., 2001, 2, 446-457
11. Vogelstein, B.; Kinzler, K.W. Cancer genes and the pathways they control. Nat. Med., 2004, 10, 789-799
12. Luo, J.; Solimini, N.L.; Elledge, S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell, 2009, 136, 823-837
13. Helleday, T.; Petermann, E.; Lundin, C.; Hodgson, B.; Sharma, R.A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer, 2008, 8, 193-204
14. Masters, J.R.; Koberle, B. Curing metastatic cancer: lessons from testicular germ-cell tumours. Nat. Rev. Cancer, 2003, 3, 517-525
15. Postel-Vinay, S.; Vanhecke, E.; Olaussen, K.A.; Lord, C.J.; Ashworth, A.; Soria, J.C. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat. Rev. Clin. Oncol., 2012, 9, 144-155
16. Ciccia, A.; Elledge, S.J. The DNA damage response: making it safe to play with knives. Mol. Cell., 2010, 40, 179-204
17. Giglia-Mari, G.; Zotter, A.; Vermeulen, W. DNA damage response. Cold Spring Harb. Perspect. Biol., 2011, 3, a000745
18. Helleday, T.; Petermann, E.; Lundin, C.; Hodgson, B.; Sharma, R.A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer, 2008, 8, 193-204
19. Helleday, T. Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis, 2010, 31, 955-960
20. Aziz, K.; Nowsheen, S.; Pantelias, G.; Iliakis, G.; Gorgoulis, V.G.; Georgakilas, A.G. Targeting DNA damage and repair: embracing the pharmacological era for successful cancer therapy. Pharmacol. Ther., 2012, 133, 334-350
21. San Filippo, J.; Sung, P.; Klein, H. Mechanism of eukaryotic homologous recombination. Annu. Rev. Biochem., 2008, 77, 229-257
22. Sonoda, E.; Takata, M.; Yamashita, Y.M.; Morrison, C.; Takeda, S. Homologous DNA recombination in vertebrate cells. Proc. Natl. Acad. Sci. U. S. A., 2001, 98, 8388-8394
23. Miyagawa, K. Clinical relevance of the homologous recombination machinery in cancer therapy. Cancer Sci., 2008, 99, 187-194
24. Pallis, A.G.; Karamouzis, M.V. DNA repair pathways and their implication in cancer treatment. Cancer Metastasis Rev., 2010, 29, 677-685
25. Sancar, A.; Lindsey-Boltz, L.A.; Unsal-Kacmaz, K.; Linn, S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem., 2004, 73, 39-85
26. Kennedy, R.D.; Chen, C.C.; Stuckert, P.; Archila, E.M.; De la Vega, M.A.; Moreau, L.A.; Shimamura, A.; D'Andrea, A.D. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J. Clin. Invest., 2007, 117, 1440-1449
27. Kee, Y.; D'Andrea, A.D. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev., 2010, 24, 1680-1694
28. Xie, K.; Doles, J.; Hemann, M.T.; Walker, G.C. Error-prone translesion synthesis mediates acquired chemoresistance. Proc. Natl. Acad. Sci. U. S. A., 2010, 107, 20792-20797
29. Bryant, H.E.; Schultz, N.; Thomas, H.D.; Parker, K.M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N.J.; Helleday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADPribose) polymerase. Nature, 2005, 434, 913-917
30. Rottenberg, S.; Jaspers, J.E.; Kersbergen, A.; van der, B.E.; Nygren, A.O.; Zander, S.A.; Derksen, P.W.; de Bruin, M.; Zevenhoven, J.; Lau, A.; Boulter, R.; Cranston, A.; O'Connor, M.J.; Martin, N.M.; Borst, P.; Jonkers, J. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. U.S.A., 2008, 105, 17079-17084
31. Chen, Y.; Zhang, L.; Hao, Q. Olaparib: a promising PARP inhibitor in ovarian cancer therapy. Arch. Gynecol. Obstet., 2013, 288, 367-374
32. Min, A.; Im, S.A.; Yoon, Y.K.; Song, S.H.; Nam, H.J.; Hur, H.S.; Kim, H.P.; Lee, K.H.; Han, S.W.; Oh, D.Y.; Kim, T.Y.; Mj, O.C.; Kim, W.H.; Bang, Y.J. RAD51C-deficient cancer cells are highly sensitive to the poly (ADP-ribose) polymerase inhibitor, olaparib. Mol. Cancer Ther., 2013. [Epub ahead of Print]
33. Itamochi, H.; Kigawa, J. Clinical trials and future potential of targeted therapy for ovarian cancer. Int. J. Clin. Oncol., 2012, 17, 430-440
34. Wilkinson-Ryan, I.; Mutch, D. A review of iniparib in ovarian cancer Expert. Opin. Investig. Drugs, 2013, 22, 399-405
35. Furuta, T.; Ueda, T.; Aune, G.; Sarasin, A.; Kraemer, K.H.; Pommier, Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res., 2002, 62, 4899-4902
36. Crul, M.; van Waardenburg, R.C.; Bocxe, S.; van Eijndhoven, M.A.; Pluim, D.; Beijnen, J.H.; Schellens, J.H. DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem. Pharmacol., 2003, 65, 275-282
37. Dunkern, T.R.; Fritz, G.; Kaina, B. Cisplatin-induced apoptosis in 43-3B and 27-1 cells defective in nucleotide excision repair. Mutat. Res., 2001, 486, 249-258
38. Chiang, Y.Y.; Chen, S.L.; Hsiao, Y.T.; Huang, C.H.; Lin, T.Y.; Chiang, I.P.; Hsu, W.H.; Chow, K.C. Nuclear expression of dynamin-related protein 1 in lung adenocarcinomas. Mod. Pathol., 2009, 22, 1139-1150
39. Nojima, K.; Hochegger, H.; Saberi, A.; Fukushima, T.; Kikuchi, K.; Yoshimura, M.; Orelli, B.J.; Bishop, D.K.; Hirano, S.; Ohzeki, M.; Ishiai, M.; Yamamoto, K.; Takata, M.; Arakawa, H.; Buerstedde, J.M.; Yamazoe, M.; Kawamoto, T.; Araki, K.; Takahashi, J.A.; Hashimoto, N.; Takeda, S.; Sonoda, E. Multiple repair pathways mediate tolerance to chemotherapeutic crosslinking agents in vertebrate cells. Cancer Res., 2005, 65, 11704-11711
40. Plooy, A.C.; van Dijk, M.; Berends, F.; Lohman, P.H. Formation and repair of DNA interstrand cross-links in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells treated with cis-diamminedichloroplatinum(II). Cancer Res., 1985, 45, 4178-4184
41. Fujiwara, Y.; Nakamura, M.; Yokoo, S. A new anticancer platinum compound, (-)-(R)-2-Aminomethyl-pyrrolidine(1,1-cyclobutanedicarboxylato) platinum(II): DNA interstrand crosslinking, repair and lethal effects in normal human, Fanconi's anaemia and xeroderma pigmentosum cells. Br. J. Cancer, 1993, 67, 1285-1292
42. Chang, I.Y.; Kim, M.H.; Kim, H.B.; Lee, D.Y.; Kim, S.H.; Kim, H.Y.; You, H.J. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin Biochem. Biophys. Res. Commun., 2005, 327, 225-233
43. Weberpals, J.; Garbuio, K.; O'Brien, A.; Clark-Knowles, K.; Doucette, S.; Antoniouk, O.; Goss, G.; Dimitroulakos, J. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int. J. Cancer, 2009, 124, 806-815
44. Lu, Y.; Mani, S.; Kandimalla, E.R.; Yu, D.; Agrawal, S.; States, J.C.; Bregman, D.B. The Cockayne syndrome group B DNA repair protein as an anti-cancer target. Int. J. Oncol., 2001, 19, 1089-1097
45. Hoy, C.A.; Thompson, L.H.; Mooney, C.L.; Salazar, E.P. Defective DNA cross-link removal in Chinese hamster cell mutants hypersensitive to bifunctional alkylating agents. Cancer Res., 1985, 45, 1737-1743
46. Andersson, B.S.; Sadeghi, T.; Siciliano, M.J.; Legerski, R.; Murray, D. Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs Cancer Chemother. Pharmacol., 1996, 38, 406-416
47. Murray, D.; Vallee-Lucic, L.; Rosenberg, E.; Andersson, B. Sensitivity of nucleotide excision repair-deficient human cells to ionizing radiation and cyclophosphamide. Anticancer Res., 2002, 22, 21-26
48. Gu, Y.; Patterson, A.V.; Atwell, G.J.; Chernikova, S.B.; Brown, J.M.; Thompson, L.H.; Wilson, W.R. Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-Activated dinitrobenzamide mustard PR-104A. Mol. Cancer Ther., 2009, 8, 1714-1723
49. De Silva, I.U.; McHugh, P.J.; Clingen, P.H.; Hartley, J.A. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol. Cell Biol., 2000, 20, 7980-7990
50. Marchini, S.; Damia, G.; Broggini, M.; Pennella, G.; Ripamonti, M.; Marsiglio, A.; Geroni, C. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms. Cancer Res., 2001, 61, 1991-1995
51. Damia, G.; Imperatori, L.; Stefanini, M.; D'Incalci, M. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int. J. Cancer, 1996, 66, 779-783
52. Clingen, P.H.; De Silva, I.U.; McHugh, P.J.; Ghadessy, F.J.; Tilby, M.J.; Thurston, D.E.; Hartley, J.A. The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136. Nucleic Acids Res., 2005, 33, 3283-3291
53. Kelner, M.J.; McMorris, T.C.; Estes, L.; Rutherford, M.; Montoya, M.; Goldstein, J.; Samson, K.; Starr, R.; Taetle, R. Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells. Unusually high sensitivity of ERCC2 and ERCC3 DNA helicase-deficient mutants in comparison to other chemotherapeutic agents. Biochem. Pharmacol., 1994, 48, 403-409
54. Kachnic, L.A.; Li, L.; Fournier, L.; Willers, H. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments. Cancer Lett., 2010, 292, 73-79
55. Ferrer, M.; de Winter, J.P.; Mastenbroek, D.C.; Curiel, D.T.; Gerritsen, W.R.; Giaccone, G.; Kruyt, F.A. Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA. Cancer Gene Ther., 2004, 11, 539-546
56. Matsushita, N.; Kitao, H.; Ishiai, M.; Nagashima, N.; Hirano, S.; Okawa, K.; Ohta, T.; Yu, D.S.; McHugh, P.J.; Hickson, I.D.; Venkitaraman, A.R.; Kurumizaka, H.; Takata, M. A FancD2-monoubiquitin fusion reveals hidden functions of Fanconi anemia core complex in DNA repair. Mol. Cell., 2005, 19, 841-847
57. van der Heijden, M.S.; Brody, J.R.; Dezentje, D.A.; Gallmeier, E.; Cunningham, S.C.; Swartz, M.J.; DeMarzo, A.M.; Offerhaus, G.J.; Isacoff, W.H.; Hruban, R.H.; Kern, S.E. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin. Cancer Res., 2005, 11, 7508-7515
58. Taniguchi, T.; Tischkowitz, M.; Ameziane, N.; Hodgson, S.V.; Mathew, C.G.; Joenje, H.; Mok, S.C.; D'Andrea, A.D. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat. Med., 2003, 9, 568-574
59. Gallmeier, E.; Calhoun, E.S.; Rago, C.; Brody, J.R.; Cunningham, S.C.; Hucl, T.; Gorospe, M.; Kohli, M.; Lengauer, C.; Kern, S.E. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options. Gastroenterology, 2006, 130, 2145-2154
60. Ishida, R.; Buchwald, M. Susceptibility of Fanconi's anemia lymphoblasts to DNA-cross-linking and alkylating agents. Cancer Res., 1982, 42, 4000-4006
61. Yabe, M.; Yabe, H.; Hamanoue, S.; Inoue, H.; Matsumoto, M.; Koike, T.; Ishiguro, H.; Morimoto, T.; Arakawa, S.; Ohshima, T.; Masukawa, A.; Miyachi, H.; Yamashita, T.; Katob, S. In vitro effect of fludarabine, cyclophosphamide, and cytosine arabinoside on chromosome breakage in Fanconi anemia patients: relevance to stem cell transplantation. Int. J. Hematol., 2007, 85, 354-361
62. Tebbs, R.S.; Hinz, J.M.; Yamada, N.A.; Wilson, J.B.; Salazar, E.P.; Thomas, C.B.; Jones, I.M.; Jones, N.J.; Thompson, L.H. New insights into the Fanconi anemia pathway from an isogenic FancG hamster CHO mutant. DNA Repair (Amst)., 2005, 4, 11-22
63. Marathi, U.K.; Howell, S.R.; Ashmun, R.A.; Brent, T.P. The Fanconi anemia complementation group C protein corrects DNA interstrand cross-link-specific apoptosis in HSC536N cells. Blood, 1996, 88, 2298-2305
64. Yamamoto, K.N.; Hirota, K.; Kono, K.; Takeda, S.; Sakamuru, S.; Xia, M.; Huang, R.; Austin, C.P.; Witt, K.L.; Tice, R.R. Characterization of environmental chemicals with potential for DNA damage using isogenic DNA repair-deficient chicken DT40 cell lines. Environ. Mol. Mutagen., 2011, 52, 547-561
65. Chen, Q.; Van der Sluis, P.C.; Boulware, D.; Hazlehurst, L.A.; Dalton, W.S. The FA/BRCA pathway is involved in melphalaninduced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood, 2005, 106, 698-705
66. Kondo, N.; Takahashi, A.; Mori, E.; Noda, T.; Zdzienicka, M.Z.; Thompson, L.H.; Helleday, T.; Suzuki, M.; Kinashi, Y.; Masunaga, S.; Ono, K.; Hasegawa, M.; Ohnishi, T. FANCD1/BRCA2 plays predominant role in the repair of DNA damage induced by ACNU or TMZ. PLoS. One, 2011, 6, e19659
67. Cohen, N.A.; Egorin, M.J.; Snyder, S.W.; Ashar, B.; Wietharn, B.E.; Pan, S.S.; Ross, D.D.; Hilton, J. Interaction of N,N',N''-triethylenethiophosphoramide and N,N',N''-triethylenephosphoramide with cellular DNA. Cancer Res., 1991, 51, 4360-4366
68. Mao, F.J.; Sidorova, J.M.; Lauper, J.M.; Emond, M.J.; Monnat, R.J. The human WRN and BLM RecQ helicases differentially regulate cell proliferation and survival after chemotherapeutic DNA damage. Cancer Res., 2010, 70, 6548-6555
69. Alli, E.; Sharma, V.B.; Hartman, A.R.; Lin, P.S.; McPherson, L.; Ford, J.M. Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC. Pharmacol., 2011, 11, 7
70. Tassone, P.; Tagliaferri, P.; Perricelli, A.; Blotta, S.; Quaresima, B.; Martelli, M.L.; Goel, A.; Barbieri, V.; Costanzo, F.; Boland, C.R.; Venuta, S. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br. J. Cancer, 2003, 88, 1285-1291
71. Quinn, J.E.; Kennedy, R.D.; Mullan, P.B.; Gilmore, P.M.; Carty, M.; Johnston, P.G.; Harkin, D.P. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res., 2003, 63, 6221-6228
72. Tran, H.M.; Shi, G.; Li, G.; Carney, J.P.; O'Malley, B.; Li, D. Mutant Nbs1 enhances cisplatin-induced DNA damage and cytotoxicity in head and neck cancer Otolaryngol. Head Neck Surg., 2004, 131, 477-484
73. Abuzeid, W.M.; Jiang, X.; Shi, G.; Wang, H.; Paulson, D.; Araki, K.; Jungreis, D.; Carney, J.; O'Malley, B.W., Jr.; Li, D. Molecular disruption of RAD50 sensitizes human tumor cells to cisplatinbased chemotherapy. J. Clin. Invest., 2009, 119, 1974-1985
74. Godthelp, B.C.; Wiegant, W.W.; Duijn-Goedhart, A.; Scharer, O.D.; van Buul, P.P.; Kanaar, R.; Zdzienicka, M.Z. Mammalian Rad51C contributes to DNA cross-link resistance, sister chromatid cohesion and genomic stability. Nucleic Acids Res., 2002, 30, 2172-2182
75. Takata, M.; Sasaki, M.S.; Tachiiri, S.; Fukushima, T.; Sonoda, E.; Schild, D.; Thompson, L.H.; Takeda, S. Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs. Mol. Cell Biol., 2001, 21, 2858-2866
76. Tsaryk, R.; Fabian, K.; Thacker, J.; Kaina, B. Xrcc2 deficiency sensitizes cells to apoptosis by MNNG and the alkylating anticancer drugs temozolomide, fotemustine and mafosfamide. Cancer Lett., 2006, 239, 305-313
77. Raaphorst, G.P.; Leblanc, M.; Li, L.F. A comparison of response to cisplatin, radiation and combined treatment for cells deficient in recombination repair pathways. Anticancer Res., 2005, 25, 53-58
78. Dhillon, K.K.; Swisher, E.M.; Taniguchi, T. Secondary mutations of BRCA1/2 and drug resistance. Cancer Sci., 2010, 10-7006
79. Kortmann, U.; McAlpine, J.N.; Xue, H.; Guan, J.; Ha, G.; Tully, S.; Shafait, S.; Lau, A.; Cranston, A.N.; O'Connor, M.J.; Huntsman, D.G.; Wang, Y.; Gilks, C.B. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin. Cancer Res., 2011, 17, 783-791
80. Evers, B.; Schut, E.; van der, B.E.; Braumuller, T.M.; Egan, D.A.; Holstege, H.; Edser, P.; Adams, D.J.; Wade-Martins, R.; Bouwman, P.; Jonkers, J. A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin. Cancer Res., 2010, 16, 99-108
81. Bello, V.E.; Aloyz, R.S.; Christodoulopoulos, G.; Panasci, L.C. Homologous recombinational repair vis-A-vis chlorambucil resistance in chronic lymphocytic leukemia. Biochem. Pharmacol., 2002, 63, 1585-1588
82. Aloyz, R.; Grzywacz, K.; Xu, Z.Y.; Loignon, M.; Alaoui-Jamali, M.A.; Panasci, L. Imatinib sensitizes CLL lymphocytes to chlorambucil. Leukemia, 2004, 18, 409-414
83. Quiros, S.; Roos, W.P.; Kaina, B. Rad51 and BRCA2-New molecular targets for sensitizing glioma cells to alkylating anticancer drugs. PLoS One, 2011, 6, e27183
84. Kondo, N.; Takahashi, A.; Mori, E.; Noda, T.; Su, X.; Ohnishi, K.; McKinnon, P.J.; Sakaki, T.; Nakase, H.; Ono, K.; Ohnishi, T. DNA ligase IV is a potential molecular target in ACNU sensitivity. Cancer Sci., 2010, 101, 1881-1885
85. Kiyohara, E.; Tamai, K.; Katayama, I.; Kaneda, Y. The combination of chemotherapy with HVJ-E containing Rad51 siRNA elicited diverse anti-tumor effects and synergistically suppressed melanoma. Gene Ther., 2012, 19(7), 734-741
86. Roos, W.P.; Nikolova, T.; Quiros, S.; Naumann, S.C.; Kiedron, O.; Zdzienicka, M.Z.; Kaina, B. Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs. DNA Repair (Amst)., 2009, 8, 72-86
87. Stachelek, G.C.; Dalal, S.; Donigan, K.A.; Campisi, H.D.; Sweasy, J.B.; Glazer, P.M. Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase beta is accentuated by BRCA2 mutation. Cancer Res., 2010, 70, 409-417
88. Short, S.C.; Giampieri, S.; Worku, M.; Alcaide-German, M.; Sioftanos, G.; Bourne, S.; Lio, K.I.; Shaked-Rabi, M.; Martindale, C. Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells. Neuro. Oncol., 2011, 13, 487-499
89. Chen, Y.W.; Cleaver, J.E.; Hanaoka, F.; Chang, C.F.; Chou, K.M. A novel role of DNA polymerase eta in modulating cellular sensitivity to chemotherapeutic agents. Mol. Cancer Res., 2006, 4, 257-265
90. Cruet-Hennequart, S.; Glynn, M.T.; Murillo, L.S.; Coyne, S.; Carty, M.P. Enhanced DNA-PK-mediated RPA2 hyperphosphorylation in DNA polymerase eta-deficient human cells treated with cisplatin and oxaliplatin. DNA Repair (Amst)., 2008, 7, 582-596
91. Albertella, M.R.; Green, C.M.; Lehmann, A.R.; O'Connor, M.J. A role for polymerase eta in the cellular tolerance to cisplatin-induced damage. Cancer Res., 2005, 65, 9799-9806
92. Lyakhovich, A.; Shekhar, M.P. RAD6B overexpression confers chemoresistance: RAD6 expression during cell cycle and its redistribution to chromatin during DNA damage-induced response. Oncogene, 2004, 23, 3097-3106
93. Okuda, T.; Lin, X.; Trang, J.; Howell, S.B. Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin. Mol. Pharmacol., 2005, 67, 1852-1860
94. Beljanski, V.; Marzilli, L.G.; Doetsch, P.W. DNA damageprocessing pathways involved in the eukaryotic cellular response to anticancer DNA cross-linking drugs. Mol. Pharmacol., 2004, 65, 1496-1506
95. Roos, W.P.; Tsaalbi-Shtylik, A.; Tsaryk, R.; Guvercin, F.; de Wind, N.; Kaina, B. The translesion polymerase Rev3L in the tolerance of alkylating anticancer drugs. Mol. Pharmacol., 2009, 76, 927-934
96. Muller, C.; Calsou, P.; Salles, B. The activity of the DNAdependent protein kinase (DNA-PK) complex is determinant in the cellular response to nitrogen mustards. Biochimie, 2000, 82, 25-28
97. Darroudi, F.; Wiegant, W.; Meijers, M.; Friedl, A.A.; van der, B.M.; Fomina, J.; van Dongen, J.J.; van Gent, D.C.; Zdzienicka, M.Z. Role of Artemis in DSB repair and guarding chromosomal stability following exposure to ionizing radiation at different stages of cell cycle. Mutat. Res., 2007, 615, 111-124
98. Fedier, A.; Moawad, A.; Haller, U.; Fink, D. p53-deficient cells display increased sensitivity to anthracyclines after loss of the catalytic subunit of the DNA-dependent protein kinase. Int. J. Oncol., 2003, 23, 1431-1437
99. Omori, S.; Takiguchi, Y.; Suda, A.; Sugimoto, T.; Miyazawa, H.; Takiguchi, Y.; Tanabe, N.; Tatsumi, K.; Kimura, H.; Pardington, P.E.; Chen, F.; Chen, D.J.; Kuriyama, T. Suppression of a DNA double-strand break repair gene, Ku70, increases radio-and chemosensitivity in a human lung carcinoma cell line. DNA Repair (Amst)., 2002, 1, 299-310
100. Sanada, M.; Takagi, Y.; Ito, R.; Sekiguchi, M. Killing and mutagenic actions of dacarbazine, a chemotherapeutic alkylating agent, on human and mouse cells: effects of Mgmt and Mlh1 mutations. DNA Repair (Amst)., 2004, 3, 413-420
101. Shiraishi, A.; Sakumi, K.; Sekiguchi, M. Increased susceptibility to chemotherapeutic alkylating agents of mice deficient in DNA repair methyltransferase. Carcinogenesis, 2000, 21, 1879-1883
102. Aquilina, G.; Ceccotti, S.; Martinelli, S.; Hampson, R.; Bignami, M. N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea sensitivity in mismatch repair-defective human cells. Cancer Res., 1998, 58, 135-141
103. Preuss, I.; Thust, R.; Kaina, B. Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs. Int. J. Cancer, 1996, 65, 506-512
104. Smith, D.G.; Brent, T.P. Response of cultured human cell lines from rhabdomyosarcoma xenografts to treatment with hloroethylnitrosoureas. Cancer Res., 1989, 49, 883-886
105. Glassner, B.J.; Weeda, G.; Allan, J.M.; Broekhof, J.L.; Carls, N.H.; Donker, I.; Engelward, B.P.; Hampson, R.J.; Hersmus, R.; Hickman, M.J.; Roth, R.B.; Warren, H.B.; Wu, M.M.; Hoeijmakers, J.H.; Samson, L.D. DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents. Mutagenesis, 1999, 14, 339-347
106. Passagne, I.; Evrard, A.; Depeille, P.; Cuq, P.; Cupissol, D.; Vian, L. O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C. Toxicol. Appl. Pharmacol., 2006, 211, 97-105
107. Passagne, I.; Evrard, A.; Winum, J.Y.; Depeille, P.; Cuq, P.; Montero, J.L.; Cupissol, D.; Vian, L. Cytotoxicity, DNA damage, and apoptosis induced by new fotemustine analogs on human melanoma cells in relation to O6-methylguanine DNA-methyltransferase expression. J. Pharmacol. Exp. Ther., 2003, 307, 816-823
108. Sato, K.; Kitajima, Y.; Koga, Y.; Miyazaki, K. The effect of o6-methylguanine-DNA methyltransferase (MGMT) and mismatch repair gene (hMLH1) status on the sensitivity to alkylating agent 1-(4-Amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea(ACNU) in gallbladder carcinoma cells. Anticancer Res., 2005, 25, 4021-4028
109. Esteller, M.; Garcia-Foncillas, J.; Andion, E.; Goodman, S.N.; Hidalgo, O.F.; Vanaclocha, V.; Baylin, S.B.; Herman, J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med., 2000, 343, 1350-1354
110. Paz, M.F.; Yaya-Tur, R.; Rojas-Marcos, I.; Reynes, G.; Pollan, M.; Aguirre-Cruz, L.; Garcia-Lopez, J.L.; Piquer, J.; Safont, M.J.; Balana, C.; Sanchez-Cespedes, M.; Garcia-Villanueva, M.; Arribas, L.; Esteller, M. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas Clin. Cancer Res., 2004, 10, 4933-4938
111. Olaussen, K.A.; Dunant, A.; Fouret, P.; Brambilla, E.; Andre, F.; Haddad, V.; Taranchon, E.; Filipits, M.; Pirker, R.; Popper, H.H.; Stahel, R.; Sabatier, L.; Pignon, J.P.; Tursz, T.; Le Chevalier, T.; Soria, J.C. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med., 2006, 355, 983-991
112. Shirota, Y.; Stoehlmacher, J.; Brabender, J.; Xiong, Y.P.; Uetake, H.; Danenberg, K.D.; Groshen, S.; Tsao-Wei, D.D.; Danenberg, P.V.; Lenz, H.J. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol., 2001, 19, 4298-4304
113. Metzger, R.; Leichman, C.G.; Danenberg, K.D.; Danenberg, P.V.; Lenz, H.J.; Hayashi, K.; Groshen, S.; Salonga, D.; Cohen, H.; Laine, L.; Crookes, P.; Silberman, H.; Baranda, J.; Konda, B.; Leichman, L. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol., 1998, 16, 309-316
114. Dabholkar, M.; Vionnet, J.; Bostick-Bruton, F.; Yu, J.J.; Reed, E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Invest., 1994, 94, 703-708
115. Lord, R.V.; Brabender, J.; Gandara, D.; Alberola, V.; Camps, C.; Domine, M.; Cardenal, F.; Sanchez, J.M.; Gumerlock, P.H.; Taron, M.; Sanchez, J.J.; Danenberg, K.D.; Danenberg, P.V.; Rosell, R. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res., 2002, 8, 2286-2291
116. Usanova, S.; Piee-Staffa, A.; Sied, U.; Thomale, J.; Schneider, A.; Kaina, B.; Koberle, B. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression Mol. Cancer, 2010, 9, 248-249
117. Taron, M.; Rosell, R.; Felip, E.; Mendez, P.; Souglakos, J.; Ronco, M.S.; Queralt, C.; Majo, J.; Sanchez, J.M.; Sanchez, J.J.; Maestre, J. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum. Mol. Genet., 2004, 13, 2443-2449
118. Aebi, S.; Fink, D.; Gordon, R.; Kim, H.K.; Zheng, H.; Fink, J.L.; Howell, S.B. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin. Cancer Res., 1997, 3, 1763-1767
119. Fink, D.; Nebel, S.; Norris, P.S.; Aebi, S.; Kim, H.K.; Haas, M.; Howell, S.B. The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. Br. J. Cancer, 1998, 77, 703-708
120. Papouli, E.; Cejka, P.; Jiricny, J. Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells. Cancer Res., 2004, 64, 3391-3394
121. Toft, N.J.; Winton, D.J.; Kelly, J.; Howard, L.A.; Dekker, M.; te, R.H.; Arends, M.J.; Wyllie, A.H.; Margison, G.P.; Clarke, A.R. Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. Proc. Natl. Acad. Sci. USA., 1999, 96, 3911-3915
122. Fink, D.; Nebel, S.; Aebi, S.; Nehme, A.; Howell, S. Loss of DNA mismatch repair due to knockout of MSH2 or PMS2 results in resistance to cisplatin and carboplatin. Int. J. Oncol., 1997, 11, 539-542
123. Francia, G.; Man, S.; Teicher, B.; Grasso, L.; Kerbel, R.S. Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents. Mol. Cell Biol., 2004, 24, 6837-6849
124. Lage, H.; Christmann, M.; Kern, M.A.; Dietel, M.; Pick, M.; Kaina, B.; Schadendorf, D. Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance. Int. J. Cancer, 1999, 80, 744-750
125. Runger, T.M.; Emmert, S.; Schadendorf, D.; Diem, C.; Epe, B.; Hellfritsch, D. Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide. J. Invest. Dermatol., 2000, 114, 34-39
126. Friedman, H.S.; Johnson, S.P.; Dong, Q.; Schold, S.C.; Rasheed, B.K.; Bigner, S.H.; Ali-Osman, F.; Dolan, E.; Colvin, O.M.; Houghton, P.; Germain, G.; Drummond, J.T.; Keir, S.; Marcelli, S.; Bigner, D.D.; Modrich, P. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res., 1997, 57, 2933-2936
127. Karran, P.; Marinus, M.G. Mismatch correction at O6-methylguanine residues in E. coli DNA. Nature, 1982, 296, 868-869
128. Fink, D.; Aebi, S.; Howell, S.B. The role of DNA mismatch repair in drug resistance. Clin. Cancer Res., 1998, 4, 1-6
129. Takahashi, M.; Koi, M.; Balaguer, F.; Boland, C.R.; Goel, A. MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. J. Biol. Chem., 2011, 286, 12157-12165
130. Martin, L.P.; Hamilton, T.C.; Schilder, R.J. Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res., 2008, 14, 1291-1295
131. Yang, Z.; Waldman, A.S.; Wyatt, M.D. DNA damage and homologous recombination signaling induced by thymidylate deprivation Biochem. Pharmacol., 2008, 76, 987-996
132. Seiple, L.; Jaruga, P.; Dizdaroglu, M.; Stivers, J.T. Linking uracil base excision repair and 5-fluorouracil toxicity in yeast. Nucleic Acids Res., 2006, 34, 140-151
133. van Waardenburg, R.C.; de Jong, L.A.; van Delft, F.; van Eijndhoven, M.A.; Bohlander, M.; Bjornsti, M.A.; Brouwer, J.; Schellens, J.H. Homologous recombination is a highly conserved determinant of the synergistic cytotoxicity between cisplatin and DNA topoisomerase I poisons. Mol. Cancer Ther., 2004, 3, 393-402
134. Nakano, T.; Katafuchi, A.; Matsubara, M.; Terato, H.; Tsuboi, T.; Masuda, T.; Tatsumoto, T.; Pack, S.P.; Makino, K.; Croteau, D.L.; Van Houten, B.; Iijima, K.; Tauchi, H.; Ide, H. Homologous recombination but not nucleotide excision repair plays a pivotal role in tolerance of DNA-protein cross-links in mammalian cells. J. Biol. Chem., 2009, 284, 27065-27076
135. Ewald, B.; Sampath, D.; Plunkett, W. ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance. Cancer Res., 2008, 68, 7947-7955
136. Tsai, M.S.; Kuo, Y.H.; Chiu, Y.F.; Su, Y.C.; Lin, Y.W. Downregulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells. J. Pharmacol. Exp. Ther., 2010, 335, 830-840
137. Issaeva, N.; Thomas, H.D.; Djureinovic, T.; Jaspers, J.E.; Stoimenov, I.; Kyle, S.; Pedley, N.; Gottipati, P.; Zur, R.; Sleeth, K.; Chatzakos, V.; Mulligan, E.A.; Lundin, C.; Gubanova, E.; Kersbergen, A.; Harris, A.L.; Sharma, R.A.; Rottenberg, S.; Curtin, N.J.; Helleday, T. 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance .Cancer Res., 2010, 70, 6268-6276
138. Rajesh, P.; Litvinchuk, A.V.; Pittman, D.L.; Wyatt, M.D. The Homologous Recombination Protein RAD51D Mediates the Processing of 6-Thioguanine Lesions Downstream of Mismatch Repair. Mol. Cancer Res., 2011, 9(2), 206-214
139. McNeill, D.R.; Lam, W.; DeWeese, T.L.; Cheng, Y.C.; Wilson, D.M., III Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites. Mol. Cancer Res., 2009, 7, 897-906
140. Jacob, D.A.; Bahra, M.; Langrehr, J.M.; Boas-Knoop, S.; Stefaniak, R.; Davis, J.; Schumacher, G.; Lippert, S.; Neumann, U.P. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells. J. Gastroenterol. Hepatol., 2007, 22, 738-748
141. Bowman, K.J.; White, A.; Golding, B.T.; Griffin, R.J.; Curtin, N.J. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064 . Br. J. Cancer, 1998, 78, 1269-1277
142. Wachters, F.M.; van Putten, J.W.; Maring, J.G.; Zdzienicka, M.Z.; Groen, H.J.; Kampinga, H.H. Selective targeting of homologous DNA recombination repair by gemcitabine. Int. J. Radiat. Oncol. Biol. Phys., 2003, 57, 553-562
143. Moses, K.; Harris, A.L.; Durkacz, B.W. Adenosinediphosphoribosyltransferase inhibitors can protect against or potentiate the cytotoxicity of S-phase acting drugs. Biochem. Pharmacol., 1988, 37, 2155-2160
144. Bergoglio, V.; Canitrot, Y.; Hogarth, L.; Minto, L.; Howell, S.B.; Cazaux, C.; Hoffmann, J.S. Enhanced expression and activity of DNA polymerase beta in human ovarian tumor cells: impact on sensitivity towards antitumor agents. Oncogene, 2001, 20, 6181-6187
145. Ohta, S.; Shimada, M.; Matsukawa, S.; Taga, T.; Yamazaki, S. Flowcytometric analysis of DNA pattern of cells derived from xeroderma pigmentosum A-hypersensitivity to vincristine, etoposide and methotrexate. Acta Paediatr. Jpn., 1990, 32, 262-268
146. Vergote, I.; Calvert, H.; Kania, M.; Kaiser, C.; Zimmermann, A.H.; Sehouli, J. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur. J. Cancer, 2009, 45, 1415-1423
147. Wang, Y.; Liu, X.; Matsuda, A.; Plunkett, W. Repair of 2'-C-cyano-2'-deoxy-1-beta-D-Arabino-pentofuranosylcytosine-induced DNA single-strand breaks by transcription-coupled nucleotide excision repair. Cancer Res., 2008, 68, 3881-3889
148. Brem, R.; Li, F.; Karran, P. Reactive oxygen species generated by thiopurine/UVA cause irreparable transcription-blocking DNA lesions. Nucleic Acids Res., 2009, 37, 1951-1961
149. Ichikawa, M.; Nakane, H.; Marra, G.; Corti, C.; Jiricny, J.; Fitch, M.; Ford, J.M.; Ikejima, M.; Shimada, T.; Yoshino, M.; Takeuchi, S.; Nakatsu, Y.; Tanaka, K. Decreased UV sensitivity, mismatch repair activity and abnormal cell cycle checkpoints in skin cancer cell lines derived from UVB-irradiated XPA-deficient mice. Mutat. Res., 2000, 459, 285-298
150. Frouin, I.; Prosperi, E.; Denegri, M.; Negri, C.; Donzelli, M.; Rossi, L.; Riva, F.; Stefanini, M.; Scovassi, A.I. Different effects of methotrexate on DNA mismatch repair proficient and deficient cells. Eur. J. Cancer, 2001, 37, 1173-1180
151. Carethers, J.M.; Chauhan, D.P.; Fink, D.; Nebel, S.; Bresalier, R.S.; Howell, S.B.; Boland, C.R. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology, 1999, 117, 123-131
152. Meyers, M.; Wagner, M.W.; Hwang, H.S.; Kinsella, T.J.; Boothman, D.A. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res., 2001, 61, 5193-5201
153. Fujita, H.; Kato, J.; Horii, J.; Harada, K.; Hiraoka, S.; Shiraha, H.; Sakaguchi, K.; Shiratori, Y. Decreased expression of hMLH1 correlates with reduced 5-fluorouracil-mediated apoptosis in colon cancer cells. Oncol. Rep., 2007, 18, 1129-1137
154. Arnold, C.N.; Goel, A.; Boland, C.R. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int. J. Cancer, 2003, 106, 66-73
155. Robinson, B.W.; Im, M.M.; Ljungman, M.; Praz, F.; Shewach, D.S. Enhanced radiosensitization with gemcitabine in mismatch repairdeficient HCT116 cells. Cancer Res., 2003, 63, 6935-6941
156. Krynetskaia, N.F.; Brenner, T.L.; Krynetski, E.Y.; Du, W.; Panetta, J.C.; Ching-Hon, P.; Evans, W.E. Msh2 deficiency attenuates but does not abolish thiopurine hematopoietic toxicity in msh2-/-mice. Mol. Pharmacol., 2003, 64, 456-465
157. Abuin, A.; Zhang, H.; Bradley, A. Genetic analysis of mouse embryonic stem cells bearing Msh3 and Msh2 single and compound mutations. Mol. Cell Biol., 2000, 20, 149-157
158. Maynard, K.; Parsons, P.G. Cross-sensitivity of methylating agents, hydroxyurea, and methotrexate in human tumor cells of the Merphenotype. Cancer Res., 1986, 46, 5009-5013
159. Wang, Z.; Li, M.; Lu, S.; Zhang, Y.; Wang, H. Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway. Cancer Biol. Ther., 2006, 5, 256-260
160. Gefen, N.; Brkic, G.; Galron, D.; Priel, E.; Ozer, J.; Benharroch, D.; Gopas, J. Acquired resistance to 6-thioguanine in melanoma cells involves the repair enzyme O6-methylguanine-DNA methyltransferase (MGMT). Cancer Biol. Ther., 2010, 9, 49-55
161. Koutsimpelas, D.; Pongsapich, W.; Heinrich, U.; Mann, S.; Mann, W.J.; Brieger, J. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells. Oncol. Rep., 2012, 27, 1135-1141
162. Singh, K.K.; Shukla, P.C.; Quan, A.; Desjardins, J.F.; Lovren, F.; Pan, Y.; Garg, V.; Gosal, S.; Garg, A.; Szmitko, P.E.; Schneider, M.D.; Parker, T.G.; Stanford, W.L.; Leong-Poi, H.; Teoh, H.; Al Omran, M.; Verma, S. BRCA2 protein deficiency exaggerates doxorubicin-induced cardiomyocyte apoptosis and cardiac failure. J. Biol. Chem., 2012, 287, 6604-6614
163. Spencer, D.M.; Bilardi, R.A.; Koch, T.H.; Post, G.C.; Nafie, J.W.; Kimura, K.; Cutts, S.M.; Phillips, D.R. DNA repair in response to anthracycline-DNA adducts: a role for both homologous recombination and nucleotide excision repair. Mutat. Res., 2008, 638, 110-121
164. Campos-Nebel, M.; Larripa, I.; Gonzalez-Cid, M. Topoisomerase II-mediated DNA damage is differently repaired during the cell cycle by non-homologous end joining and homologous recombination. PLoS. One, 2010, 5, e12541
165. Abbott, D.W.; Freeman, M.L.; Holt, J.T. Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J. Natl. Cancer Inst., 1998, 90, 978-985
166. Elliott, S.L.; Crawford, C.; Mulligan, E.; Summerfield, G.; Newton, P.; Wallis, J.; Mainou-Fowler, T.; Evans, P.; Bedwell, C.; Durkacz, B.W.; Willmore, E. Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia. Br. J. Haematol., 2011, 152, 61-71
167. Imamura, O.; Fujita, K.; Shimamoto, A.; Tanabe, H.; Takeda, S.; Furuichi, Y.; Matsumoto, T. Bloom helicase is involved in DNA surveillance in early S phase in vertebrate cells. Oncogene, 2001, 20, 1143-1151
168. Abe, H.; Wada, M.; Kohno, K.; Kuwano, M. Altered drug sensitivities to anticancer agents in radiation-sensitive DNA repair deficient yeast mutants. Anticancer Res., 1994, 14, 1807-1810
169. Keszenman, D.J.; Salvo, V.A.; Nunes, E. Effects of bleomycin on growth kinetics and survival of Saccharomyces cerevisiae: a model of repair pathways. J. Bacteriol., 1992, 174, 3125-3132
170. Letavayova, L.; Markova, E.; Hermanska, K.; Vlckova, V.; Vlasakova, D.; Chovanec, M.; Brozmanova, J. Relative contribution of homologous recombination and non-homologous end-joining to DNA double-strand break repair after oxidative stress in Saccharomyces cerevisiae. DNA Repair (Amst)., 2006, 5, 602-610
171. Moore, C.W. Responses of radiation-sensitive mutants of Saccharomyces cerevisiae to lethal effects of bleomycin. Mutat. Res., 1978, 51, 165-180
172. Rooney, S.; Alt, F.W.; Lombard, D.; Whitlow, S.; Eckersdorff, M.; Fleming, J.; Fugmann, S.; Ferguson, D.O.; Schatz, D.G.; Sekiguchi, J. Defective DNA repair and increased genomic instability in Artemis-deficient murine cells. J. Exp. Med., 2003, 197, 553-565
173. Mohapatra, S.; Kawahara, M.; Khan, I.S.; Yannone, S.M.; Povirk, L.F. Restoration of G1 chemo/radioresistance and double-strandbreak repair proficiency by wild-type but not endonucleasedeficient. Artemis Nucleic Acids Res., 2011, 39, 6500-6510
174. Kim, S.H.; Kim, D.; Han, J.S.; Jeong, C.S.; Chung, B.S.; Kang, C.D.; Li, G.C. Ku autoantigen affects the susceptibility to anticancer drugs. Cancer Res., 1999, 59, 4012-4017
175. Adachi, N.; Ishino, T.; Ishii, Y.; Takeda, S.; Koyama, H. DNA ligase IV-deficient cells are more resistant to ionizing radiation in the absence of Ku70: Implications for DNA double-strand break repair. Proc. Natl. Acad. Sci. U.S.A., 2001, 98, 12109-12113
176. Poot, M.; Jin, X.; Hill, J.P.; Gollahon, K.A.; Rabinovitch, P.S. Distinct functions for WRN and TP53 in a shared pathway of cellular response to 1-beta-D-Arabinofuranosylcytosine and bleomycin. Exp. Cell Res., 2004, 296, 327-336
177. Hook, G.J.; Kwok, E.; Heddle, J.A. Sensitivity of Bloom syndrome fibroblasts to mitomycin C. Mutat. Res., 1984, 131, 223-230
178. Chu, W.K.; Hanada, K.; Kanaar, R.; Hickson, I.D. BLM has early and late functions in homologous recombination repair in mouse embryonic stem cells. Oncogene, 2010, 29, 4705-4714
179. Moynahan, M.E.; Cui, T.Y.; Jasin, M. Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res., 2001, 61, 4842-4850
180. Yun, J.; Zhong, Q.; Kwak, J.Y.; Lee, W.H. Hypersensitivity of Brca1-deficient MEF to the DNA interstrand crosslinking agent mitomycin C is associated with defect in homologous recombination repair and aberrant S-phase arrest. Oncogene, 2005, 24, 4009-4016
181. Hattori, H.; Skoulidis, F.; Russell, P.; Venkitaraman, A.R. Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor. Mol. Cancer Ther., 2011, 10, 670-678
182. Hanlon Newell, A.E.; Hemphill, A.; Akkari, Y.M.; Hejna, J.; Moses, R.E.; Olson, S.B. Loss of homologous recombination or non-homologous end-joining leads to radial formation following DNA interstrand crosslink damage. Cytogenet. Genome Res., 2008, 121, 174-180
183. Essers, J.; Hendriks, R.W.; Swagemakers, S.M.; Troelstra, C.; de Wit, J.; Bootsma, D.; Hoeijmakers, J.H.; Kanaar, R. Disruption of mouse RAD54 reduces ionizing radiation resistance and homologous recombination. Cell, 1997, 89, 195-204
184. Essers, J.; van Steeg, H.; de Wit, J.; Swagemakers, S.M.; Vermeij, M.; Hoeijmakers, J.H.; Kanaar, R. Homologous and nonhomologous recombination differentially affect DNA damage repair in mice. EMBO J., 2000, 19, 1703-1710
185. Musio, A.; Marrella, V.; Sobacchi, C.; Rucci, F.; Fariselli, L.; Giliani, S.; Lanzi, G.; Notarangelo, L.D.; Delia, D.; Colombo, R.; Vezzoni, P.; Villa, A. Damaging-Agent sensitivity of Artemisdeficient cell lines. Eur. J. Immunol., 2005, 35, 1250-1256
186. Agrelo, R.; Cheng, W.H.; Setien, F.; Ropero, S.; Espada, J.; Fraga, M.F.; Herranz, M.; Paz, M.F.; Sanchez-Cespedes, M.; Artiga, M.J.; Guerrero, D.; Castells, A.; von Kobbe, C.; Bohr, V.A.; Esteller, M. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 8822-8827
187. Cheng, W.H.; von Kobbe, C.; Opresko, P.L.; Arthur, L.M.; Komatsu, K.; Seidman, M.M.; Carney, J.P.; Bohr, V.A. Linkage between Werner syndrome protein and the Mre11 complex via Nbs1. J. Biol. Chem., 2004, 279, 21169-21176
188. Katsube, T.; Mori, M.; Tsuji, H.; Shiomi, T.; Shiomi, N.; Onoda, M. Differences in sensitivity to DNA-damaging Agents between XRCC4-and Artemis-deficient human cells. J. Radiat. Res. (Tokyo), 2011, 52, 415-424
189. Jaspers, N.G.; Raams, A.; Silengo, M.C.; Wijgers, N.; Niedernhofer, L.J.; Robinson, A.R.; Giglia-Mari, G.; Hoogstraten, D.; Kleijer, W.J.; Hoeijmakers, J.H.; Vermeulen, W. First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure. Am. J. Hum. Genet., 2007, 80, 457-466
190. Kano, Y.; Fujiwara, Y. Roles of DNA interstrand crosslinking and its repair in the induction of sister-chromatid exchange and a higher induction in Fanconi's anemia cells. Mutat. Res., 1981, 81, 365-375
191. Tian, M.; Shinkura, R.; Shinkura, N.; Alt, F.W. Growth retardation, early death, and DNA repair defects in mice deficient for the nucleotide excision repair enzyme XPF. Mol. Cell Biol., 2004, 24, 1200-1205
192. Carreau, M.; Alon, N.; Bosnoyan-Collins, L.; Joenje, H.; Buchwald, M. Drug sensitivity spectra in Fanconi anemia lymphoblastoid cell lines of defined complementation groups. Mutat. Res., 1999, 435, 103-109
193. Casado, J.A.; Rio, P.; Marco, E.; Garcia-Hernandez, V.; Domingo, A.; Perez, L.; Tercero, J.C.; Vaquero, J.J.; Albella, B.; Gago, F.; Bueren, J.A. Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Mol. Cancer Ther., 2008, 7, 1309-1318
194. Godthelp, B.C.; van Buul, P.P.; Jaspers, N.G.; Elghalbzouri-Maghrani, E.; Duijn-Goedhart, A.; Arwert, F.; Joenje, H.; Zdzienicka, M.Z. Cellular characterization of cells from the Fanconi anemia complementation group, FA-D1/BRCA2. Mutat. Res., 2006, 601, 191-201
195. Kachnic, L.A.; Li, L.; Fournier, L.; Ferraiolo, N.; Dahm-Daphi, J.; Borgmann, K.; Willers, H. FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons. Cancer Lett., 2011, 305(1), 86-93
196. Carvalho, H.; Garrido, L.M.; Furlan, R.L.; Padilla, G.; Agnoletto, M.; Guecheva, T.; Henriques, J.A.; Saffi, J.; Menck, C.F. DNA damage induced by the anthracycline cosmomycin D in DNA repair-deficient cells. Cancer Chemother. Pharmacol., 2010, 65, 989-994
197. Moraes, M.C.; de Andrade, A.Q.; Carvalho, H.; Guecheva, T.; Agnoletto, M.H.; Henriques, J.A.; Sarasin, A.; Stary, A.; Saffi, J.; Menck, C.F. Both XPA and DNA polymerase eta are necessary for the repair of doxorubicin-induced DNA lesions. Cancer Lett., 2012, 314, 108-118
198. Wang, X.W.; Vermeulen, W.; Coursen, J.D.; Gibson, M.; Lupold, S.E.; Forrester, K.; Xu, G.; Elmore, L.; Yeh, H.; Hoeijmakers, J.H.; Harris, C.C. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev., 1996, 10, 1219-1232
199. Robles, A.I.; Wang, X.W.; Harris, C.C. Drug-induced apoptosis is delayed and reduced in XPD lymphoblastoid cell lines: possible role of TFIIH in p53-mediated apoptotic cell death. Oncogene, 1999, 18, 4681-4688
200. Weksberg, R.; Buchwald, M.; Sargent, P.; Thompson, M.W.; Siminovitch, L. Specific cellular defects in patients with Fanconi anemia. J. Cell Physiol., 1979, 101, 311-323
201. Fedier, A.; Schwarz, V.A.; Walt, H.; Carpini, R.D.; Haller, U.; Fink, D. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int. J. Cancer, 2001, 93, 571-576
202. Vernole, P.; Tedeschi, B.; Tentori, L.; Levati, L.; Argentin, G.; Cicchetti, R.; Forini, O.; Graziani, G.; D'Atri, S. Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin. Mutat. Res., 2006, 594, 63-77
203. Wu, M.; Zhang, Z.; Che, W. Suppression of a DNA base excision repair gene, hOGG1, increases bleomycin sensitivity of human lung cancer cell line. Toxicol. Appl. Pharmacol., 2008, 228, 395-402
204. Chatterjee, S.; Cheng, M.F.; Berger, N.A. Hypersensitivity to clinically useful alkylating agents and radiation in poly(ADP-ribose) polymerase-deficient cell lines. Cancer Commun., 1990, 2, 401-407
205. Liu, S.; Lai, Y.; Zhao, W.; Wu, M.; Zhang, Z. Links between DNA polymerase beta expression and sensitivity to bleomycin. Toxicology, 2011, 281(1-3), 63-69
206. Pietruska, J.R.; Johnston, T.; Zhitkovich, A.; Kane, A.B. XRCC1 deficiency sensitizes human lung epithelial cells to genotoxicity by crocidolite asbestos and Libby amphibole. Environ. Health Perspect., 2010, 118, 1707-1713
207. Kohzaki, M.; Hatanaka, A.; Sonoda, E.; Yamazoe, M.; Kikuchi, K.; Vu, T.N.; Szuts, D.; Sale, J.E.; Shinagawa, H.; Watanabe, M.; Takeda, S. Cooperative roles of vertebrate Fbh1 and Blm DNA helicases in avoidance of crossovers during recombination initiated by replication fork collapse. Mol. Cell Biol., 2007, 27, 2812-2820
208. Imamura, O.; Fujita, K.; Itoh, C.; Takeda, S.; Furuichi, Y.; Matsumoto, T. Werner and Bloom helicases are involved in DNA repair in a complementary fashion. Oncogene, 2002, 21, 954-963
209. Qing, Y.; Yamazoe, M.; Hirota, K.; Dejsuphong, D.; Sakai, W.; Yamamoto, K.N.; Bishop, D.K.; Wu, X.; Takeda, S. The epistatic relationship between BRCA2 and the other RAD51 mediators in homologous recombination. PLoS. Genet., 2011, 7, e1002148
210. Nomura, Y.; Adachi, N.; Koyama, H. Human Mus81 and FANCB independently contribute to repair of DNA damage during replication. Genes Cells, 2007, 12, 1111-1122
211. Hinz, J.M.; Helleday, T.; Meuth, M. Reduced apoptotic response to camptothecin in CHO cells deficient in XRCC3. Carcinogenesis, 2003, 24, 249-253
212. Arnaudeau, C.; Lundin, C.; Helleday, T. DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. J. Mol. Biol., 2001, 307, 1235-1245
213. Lebel, M.; Leder, P. A deletion within the murine Werner syndrome helicase induces sensitivity to inhibitors of topoisomerase and loss of cellular proliferative capacity. Proc. Natl. Acad. Sci. USA, 1998, 95, 13097-13102
214. Tian, X.; Chen, G.; Xing, H.; Weng, D.; Guo, Y.; Ma, D. The relationship between the down-regulation of DNA-PKcs or Ku70 and the hemosensitization in human cervical carcinoma cell line HeLa. Oncol. Rep., 2007, 18, 927-932
215. Aggarwal, M.; Sommers, J.A.; Shoemaker, R.H.; Brosh, R.M., Jr. Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress. Proc. Natl. Acad. Sci. USA, 2011, 108, 1525-1530
216. Christmann, M.; Tomicic, M.T.; Gestrich, C.; Roos, W.P.; Bohr, V.A.; Kaina, B. WRN protects against topo I but not topo II inhibitors by preventing DNA break formation. DNA Repair (Amst.), 2008, 7, 1999-2009
217. James, E.; Waldron-Lynch, M.G.; Saif, M.W. Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs, 2009, 20, 634-638
218. Ambrosini, G.; Seelman, S.L.; Qin, L.X.; Schwartz, G.K. The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner Cancer Res., 2008, 68, 2312-2320
219. Davidson, D.; Coulombe, Y.; Martinez-Marignac, V.L.; Amrein, L.; Grenier, J.; Hodkinson, K.; Masson, J.Y.; Aloyz, R.; Panasci, L. Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells. Invest. New Drugs, 2012, 30(3), 1248-1256
220. Treszezamsky, A.D.; Kachnic, L.A.; Feng, Z.; Zhang, J.; Tokadjian, C.; Powell, S.N. BRCA1-and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res., 2007, 67, 7078-7081
221. Adachi, N.; Iiizumi, S.; Koyama, H. Evidence for a role of vertebrate Rad52 in the repair of topoisomerase II-mediated DNA damage. DNA Cell Biol., 2005, 24, 388-393
222. Wang, J.; Pluth, J.M.; Cooper, P.K.; Cowan, M.J.; Chen, D.J.; Yannone, S.M. Artemis deficiency confers a DNA double-strand break repair defect and Artemis phosphorylation status is altered by DNA damage and cell cycle progression. DNA Repair (Amst)., 2005, 4, 556-570
223. Hosono, Y.; Abe, T.; Ishiai, M.; Takata, M.; Enomoto, T.; Seki, M. The role of SNM1 family nucleases in etoposide-induced apoptosis. Biochem. Biophys. Res. Commun., 2011, 410, 568-573
224. Jin, S.; Inoue, S.; Weaver, D.T. Differential etoposide sensitivity of cells deficient in the Ku and DNA-PKcs components of the DNAdependent protein kinase. Carcinogenesis, 1998, 19, 965-971
225. Shih, S.J.; Erbele, T.; Chen, A.Y. Ku86 modulates DNA topoisomerase I-mediated radiosensitization, but not cytotoxicity, in mammalian cells. Cancer Res., 2005, 65, 9194-9199
226. Adachi, N.; Suzuki, H.; Iiizumi, S.; Koyama, H. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage. J. Biol. Chem., 2003, 278, 35897-35902
227. So, S.; Adachi, N.; Lieber, M.R.; Koyama, H. Genetic interactions between BLM and DNA ligase IV in human cells. J. Biol. Chem., 2004, 279, 55433-55442
228. Chatterjee, S.; Cheng, M.F.; Trivedi, D.; Petzold, S.J.; Berger, N.A. Camptothecin hypersensitivity in poly(adenosine diphosphateribose) polymerase-deficient cell lines. Cancer Commun., 1989, 1, 389-394
229. Vermeulen, C.; Bertocci, B.; Begg, A.C.; Vens, C. Ionizing radiation sensitivity of DNA polymerase lambda-deficient cells. Radiat. Res., 2007, 168, 683-688
230. Plo, I.; Liao, Z.Y.; Barcelo, J.M.; Kohlhagen, G.; Caldecott, K.W.; Weinfeld, M.; Pommier, Y. Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase Imediated DNA lesions. DNA Repair (Amst)., 2003, 2, 1087-1100
231. Barrows, L.R.; Holden, J.A.; Anderson, M.; D'Arpa, P. The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication. Mutat. Res., 1998, 408, 103-110
232. Smith, L.M.; Willmore, E.; Austin, C.A.; Curtin, N.J. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin. Cancer Res., 2005, 11, 8449-8457
233. Miknyoczki, S.J.; Jones-Bolin, S.; Pritchard, S.; Hunter, K.; Zhao, H.; Wan, W.; Ator, M.; Bihovsky, R.; Hudkins, R.; Chatterjee, S.; Klein-Szanto, A.; Dionne, C.; Ruggeri, B. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol. Cancer Ther., 2003, 2, 371-382
234. Calabrese, C.R.; Almassy, R.; Barton, S.; Batey, M.A.; Calvert, A.H.; Canan-Koch, S.; Durkacz, B.W.; Hostomsky, Z.; Kumpf, R.A.; Kyle, S.; Li, J.; Maegley, K.; Newell, D.R.; Notarianni, E.; Stratford, I.J.; Skalitzky, D.; Thomas, H.D.; Wang, L.Z.; Webber, S.E.; Williams, K.J.; Curtin, N.J. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst., 2004, 96, 56-67
235. Takahashi, T.; Min, Z.; Uchida, I.; Arita, M.; Watanabe, Y.; Koi, M.; Hemmi, H. Hypersensitivity in DNA mismatch repair-deficient colon carcinoma cells to DNA polymerase reaction inhibitors. Cancer Lett., 2005, 220, 85-93
236. Eriksson, A.; Lewensoh, R.; Larsson, R.; Nilsson, A. DNAdependent protein kinase in leukaemia cells and correlation with drug sensitivity Anticancer Res., 2002, 22, 1787-1793
237. Hanley, M.L.; Elion, G.B.; Colvin, O.M.; Modrich, P.L.; Keir, S.; Adams, D.J.; Bigner, D.D.; Friedman, H.S. Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors. Cancer Chemother. Pharmacol., 1998, 42, 479-482
238. Egawa, C.; Miyoshi, Y.; Takamura, Y.; Taguchi, T.; Tamaki, Y.; Noguchi, S. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int. J. Cancer, 2001, 95, 255-259
239. Jiang, W.; Lu, Y.; Chen, Z.; Chen, S.; Zhang, M.; Jin, L.; Lou, J.; He, J. Studying the genotoxicity of vincristine on human lymphocytes using comet assay, micronucleus assay and TCR gene mutation test in vitro. Toxicology, 2008, 252, 113-117
240. Branham, M.T.; Nadin, S.B.; Vargas-Roig, L.M.; Ciocca, D.R. DNA damage induced by paclitaxel and DNA repair capability of peripheral blood lymphocytes as evaluated by the alkaline comet assay. Mutat. Res., 2004, 560, 11-17
241. Nowsheen, S.; Bonner, J.A.; Lobuglio, A.F.; Trummell, H.; Whitley, A.C.; Dobelbower, M.C.; Yang, E.S. Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer. PLoS. One, 2011, 6, e24148
242. Li, L.; Wang, H.; Yang, E.S.; Arteaga, C.L.; Xia, F. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res., 2008, 68, 9141-9146
243. Rosell, R.; Molina, M.A.; Costa, C.; Simonetti, S.; Gimenez-Capitan, A.; Bertran-Alamillo, J.; Mayo, C.; Moran, T.; Mendez, P.; Cardenal, F.; Isla, D.; Provencio, M.; Cobo, M.; Insa, A.; Garcia-Campelo, R.; Reguart, N.; Majem, M.; Viteri, S.; Carcereny, E.; Porta, R.; Massuti, B.; Queralt, C.; de, A., I; Sanchez, J.M.; Sanchez-Ronco, M.; Mate, J.L.; Ariza, A.; Benlloch, S.; Sanchez, J.J.; Bivona, T.G.; Sawyers, C.L.; Taron, M. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinibtreated advanced non-small-cell lung cancer patients with EGFR mutations. Clin. Cancer Res., 2011, 17, 1160-1168
244. Mizutani, A.; Okada, T.; Shibutani, S.; Sonoda, E.; Hochegger, H.; Nishigori, C.; Miyachi, Y.; Takeda, S.; Yamazoe, M. Extensive chromosomal breaks are induced by tamoxifen and estrogen in DNA repair-deficient cells. Cancer Res., 2004, 64, 3144-3147
245. Nagalingam, A.; Tighiouart, M.; Ryden, L.; Joseph, L.; Landberg, G.; Saxena, N.K.; Sharma, D. Med1 plays a critical role in the development of tamoxifen resistance. Carcinogenesis, 2012, 33, 918-930
246. Carthew, P.; Martin, E.A.; White, I.N.; De Matteis, F.; Edwards, R.E.; Dorman, B.M.; Heydon, R.T.; Smith, L.L. Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: promotion by Phenobarbital. Cancer Res., 1995, 55, 544-547
247. Gaikwad, N.W.; Bodell, W.J. Peroxidase-mediated dealkylation of tamoxifen, detected by electrospray ionization-mass spectrometry, and activation to form DNA adducts. Free Radic. Biol. Med., 2012, 52, 340-347
248. Martin, E.A.; Brown, K.; Gaskell, M.; Al Azzawi, F.; Garner, R.C.; Boocock, D.J.; Mattock, E.; Pring, D.W.; Dingley, K.; Turteltaub, K.W.; Smith, L.L.; White, I.N. Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res., 2003, 63, 8461-8465
249. Wen, J.; Li, R.; Lu, Y.; Shupnik, M.A. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions. Oncogene, 2009, 28, 575-586
250. Hosey, A.M.; Gorski, J.J.; Murray, M.M.; Quinn, J.E.; Chung, W.Y.; Stewart, G.E.; James, C.R.; Farragher, S.M.; Mulligan, J.M.; Scott, A.N.; Dervan, P.A.; Johnston, P.G.; Couch, F.J.; Daly, P.A.; Kay, E.; McCann, A.; Mullan, P.B.; Harkin, D.P. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J. Natl. Cancer Inst., 2007, 99, 1683-1694
251. Tavecchio, M.; Simone, M.; Erba, E.; Chiolo, I.; Liberi, G.; Foiani, M.; D'Incalci, M.; Damia, G. Role of homologous recombination in trabectedin-induced DNA damage. Eur. J. Cancer, 2008, 44, 609-618
252. Damia, G.; Silvestri, S.; Carrassa, L.; Filiberti, L.; Faircloth, G.T.; Liberi, G.; Foiani, M.; D'Incalci, M. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int. J. Cancer, 2001, 92, 583-588
253. Zewail-Foote, M.; Li, V.S.; Kohn, H.; Bearss, D.; Guzman, M.; Hurley, L.H. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repairdependent toxicities of this antitumor agent. Chem. Biol., 2001, 8, 1033-1049
254. Erba, E.; Bergamaschi, D.; Bassano, L.; Damia, G.; Ronzoni, S.; Faircloth, G.T.; D'Incalci, M. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur. J. Cancer, 2001, 37, 97-105
255. Takebayashi, Y.; Pourquier, P.; Zimonjic, D.B.; Nakayama, K.; Emmert, S.; Ueda, T.; Urasaki, Y.; Kanzaki, A.; Akiyama, S.I.; Popescu, N.; Kraemer, K.H.; Pommier, Y. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat. Med., 2001, 7, 961-966
256. Takebayashi, Y.; Pourquier, P.; Yoshida, A.; Kohlhagen, G.; Pommier, Y. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove. Proc. Natl. Acad. Sci. USA, 1999, 96, 7196-7201
257. Soares, D.G.; Escargueil, A.E.; Poindessous, V.; Sarasin, A.; de Gramont, A.; Bonatto, D.; Henriques, J.A.; Larsen, A.K. Replication and homologous recombination repair regulate DNA doublestrand break formation by the antitumor alkylator ecteinascidin 743. Proc. Natl. Acad. Sci. USA, 2007, 104, 13062-13067
258. Feuerhahn, S.; Giraudon, C.; Martinez-Diez, M.; Bueren-Calabuig, J.A.; Galmarini, C.M.; Gago, F.; Egly, J.M. XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloids. Chem. Biol., 2011, 18, 988-999
259. Petermann, E.; Orta, M.L.; Issaeva, N.; Schultz, N.; Helleday, T. Hydroxyurea-stalled replication forks become progressively inactivated and require two different RAD51-mediated pathways for restart and repair. Mol. Cell., 2010, 37, 492-502
260. Davies, S.L.; North, P.S.; Dart, A.; Lakin, N.D.; Hickson, I.D. Phosphorylation of the Bloom's syndrome helicase and its role in recovery from S-phase arrest. Mol. Cell Biol., 2004, 24, 1279-1291
261. Liu, N.; Lim, C.S. Differential roles of XRCC2 in homologous recombinational repair of stalled replication forks. J. Cell Biochem., 2005, 95, 942-954
262. Urbin, S.S.; Elvers, I.; Hinz, J.M.; Helleday, T.; Thompson, L.H. Uncoupling of RAD51 focus formation and cell survival after replication fork stalling in RAD51D null CHO cells. Environ. Mol. Mutagen., 2012, 53, 114-124
263. Lundin, C.; Erixon, K.; Arnaudeau, C.; Schultz, N.; Jenssen, D.; Meuth, M.; Helleday, T. Different roles for nonhomologous end joining and homologous recombination following replication arrest in mammalian cells. Mol. Cell Biol., 2002, 22, 5869-5878
264. Zhang, C.; Liu, Y.; Hu, Z.; An, L.; He, Y.; Hang, H. Targeted deletion of mouse Rad1 leads to deficient cellular DNA damage responses. Protein Cell., 2011, 2, 410-422
265. Saintigny, Y.; Delacote, F.; Vares, G.; Petitot, F.; Lambert, S.; Averbeck, D.; Lopez, B.S. Characterization of homologous recom bination induced by replication inhibition in mammalian cells. EMBO J., 2001, 20, 3861-3870
266. Yang, Y.G.; Cortes, U.; Patnaik, S.; Jasin, M.; Wang, Z.Q. Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks. Oncogene, 2004, 23, 3872-3882
267. Johnstone, P.; Reifsteck, C.; Kohler, S.; Worland, P.; Olson, S.; Moses, R.E. Fanconi anemia group A and D cell lines respond normally to inhibitors of cell cycle regulation. Somat. Cell Mol. Genet., 1997, 23, 371-377
268. Bi, X.; Slater, D.M.; Ohmori, H.; Vaziri, C. DNA polymerase kappa is specifically required for recovery from the benzo[a]pyrene-dihydrodiol epoxide (BPDE)-induced S-phase checkpoint. J. Biol. Chem., 2005, 280, 22343-22355
269. Sato, M.; Niki, T.; Tokou, T.; Suzuki, K.; Fujimura, M.; Ichiishi, A. Genetic analysis of the Neurospora crassa RAD14 homolog mus-43 and the RAD10 homolog mus-44 reveals that they belong to the mus-38 pathway of two nucleotide excision repair systems. Genes Genet. Syst., 2008, 83, 1-11
270. Neri, P.; Ren, L.; Gratton, K.; Stebner, E.; Johnson, J.; Klimowicz, A.; Duggan, P.; Tassone, P.; Mansoor, A.; Stewart, D.A.; Lonial, S.; Boise, L.H.; Bahlis, N.J. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. Blood, 2011, 118, 6368-6379
271. Fishel, M.L.; Colvin, E.S.; Luo, M.; Kelley, M.R.; Robertson, K.A. Inhibition of the redox function of APE1/Ref-1 in myeloid leukemia cell lines results in a hypersensitive response to retinoic acidinduced differentiation and apoptosis. Exp. Hematol., 2010, 38, 1178-1188
272. Berry, D.M.; Williams, K.; Meckling-Gill, K.A. All trans retinoic acid induces apoptosis in acute promyelocytic NB4 cells when combined with isoquinolinediol, a poly(ADP-ribose) polymerase inhibitor. Leuk. Res., 2000, 24, 307-316
273. Holleman, A.; den Boer, M.L.; Kazemier, K.M.; Beverloo, H.B.; von Bergh, A.R.; Janka-Schaub, G.E.; Pieters, R. Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia. Blood, 2005, 106, 1817-1823
274. Okui, T.; Fujiwara, Y. Inhibition of human excision DNA repair by inorganic arsenic and the co-mutagenic effect in V79 Chinese hamster cells. Mutat. Res., 1986, 172, 69-76
275. Liu, S.Y.; Wen, C.Y.; Lee, Y.J.; Lee, T.C. XPC silencing sensitizes glioma cells to arsenic trioxide via increased oxidative damage. Toxicol. Sci., 2010, 116, 183-193
276. Ren, S.; Xu, C.; Cui, Z.; Yu, Y.; Xu, W.; Wang, F.; Lu, J.; Wei, M.; Lu, X.; Gao, X.; Liang, Y.; Mao, J.H.; Sun, Y. Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer. J. Mol. Med. (Berl.), 2012, 90(10), 1121-1132
277. Diouf, B.; Cheng, Q.; Krynetskaia, N.F.; Yang, W.; Cheok, M.; Pei, D.; Fan, Y.; Cheng, C.; Krynetskiy, E.Y.; Geng, H.; Chen, S.; Thierfelder, W.E.; Mullighan, C.G.; Downing, J.R.; Hsieh, P.; Pui, C.H.; Relling, M.V.; Evans, W.E. Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat. Med., 2011, 17, 1298-1303
278. Imesch, P.; Dedes, K.J.; Furlato, M.; Fink, D.; Fedier, A. MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells. Int. J. Oncol., 2009, 35, 631-640
279. Takata, M.; Sasaki, M.S.; Sonoda, E.; Fukushima, T.; Morrison, C.; Albala, J.S.; Swagemakers, S.M.; Kanaar, R.; Thompson, L.H.; Takeda, S. The Rad51 paralog Rad51B promotes homologous recombinational repair. Mol. Cell Biol., 2000, 20, 6476-6482
280. Jiang, Y.; Guo, C.; Vasko, M.R.; Kelley, M.R. Implications of apurinic/apyrimidinic endonuclease in reactive oxygen signaling response after cisplatin treatment of dorsal root ganglion neurons. Cancer Res., 2008, 68, 6425-6434
281. Wang, D.; Xiang, D.B.; Yang, X.Q.; Chen, L.S.; Li, M.X.; Zhong, Z.Y.; Zhang, Y.S. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer, 2009, 66, 298-304
282. Chattopadhyay, R.; Das, S.; Maiti, A.K.; Boldogh, I.; Xie, J.; Hazra, T.K.; Kohno, K.; Mitra, S.; Bhakat, K.K. Regulatory role of human AP-endonuclease (APE1/Ref-1) in YB-1-mediated activation of the multidrug resistance gene MDR1. Mol. Cell Biol., 2008, 28, 7066-7080
283. McNeill, D.R.; Wilson, D.M., III A dominant-negative form of the major human abasic endonuclease enhances cellular sensitivity to laboratory and clinical DNA-damaging agents. Mol. Cancer Res., 2007, 5, 61-70
284. Ochs, K.; Sobol, R.W.; Wilson, S.H.; Kaina, B. Cells deficient in DNA polymerase beta are hypersensitive to alkylating agentinduced apoptosis and chromosomal breakage. Cancer Res., 1999, 59, 1544-1551
285. Horton, J.K.; Joyce-Gray, D.F.; Pachkowski, B.F.; Swenberg, J.A.; Wilson, S.H. Hypersensitivity of DNA polymerase beta null mouse fibroblasts reflects accumulation of cytotoxic repair intermediates from site-specific alkyl DNA lesions. DNA Repair (Amst)., 2003, 2, 27-48
286. Yang, J.; Parsons, J.; Nicolay, N.H.; Caporali, S.; Harrington, C.F.; Singh, R.; Finch, D.; D'Atri, S.; Farmer, P.B.; Johnston, P.G.; McKenna, W.G.; Dianov, G.; Sharma, R.A. Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy. Oncogene, 2010, 29, 463-468
287. Kothandapani, A.; Dangeti, V.S.; Brown, A.R.; Banze, L.A.; Wang, X.H.; Sobol, R.W.; Patrick, S.M. Novel role of base excision repair (BER) in mediating cisplatin cytotoxicity. J. Biol. Chem., 2011, 286(16), 14564-14574
288. Cortellino, S.; Turner, D.; Masciullo, V.; Schepis, F.; Albino, D.; Daniel, R.; Skalka, A.M.; Meropol, N.J.; Alberti, C.; Larue, L.; Bellacosa, A. The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proc. Natl. Acad. Sci. USA, 2003, 100, 15071-15076
289. Sansom, O.J.; Zabkiewicz, J.; Bishop, S.M.; Guy, J.; Bird, A.; Clarke, A.R. MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine. Oncogen, 2003, 22, 7130-7136
290. Guay, D.; Garand, C.; Reddy, S.; Schmutte, C.; Lebel, M. The human endonuclease III enzyme is a relevant target to potentiate cisplatin cytotoxicity in Y-box-binding protein-1 overexpressing tumor cells. Cancer Sci., 2008, 99, 762-769
291. Durant, S.T.; Morris, M.M.; Illand, M.; McKay, H.J.; McCormick, C.; Hirst, G.L.; Borts, R.H.; Brown, R. Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes. Curr. Biol., 1999, 9, 51-54
292. Fishel, M.L.; Delaney, S.M.; Friesen, L.D.; Hansen, R.J.; Zuhowski, E.G.; Moschel, R.C.; Egorin, M.J.; Dolan, M.E. Enhancement of platinum-induced cytotoxicity by O6-benzylguanine. Mol. Cancer Ther., 2003, 2, 633-640
293. Takenaka, T.; Yoshino, I.; Kouso, H.; Ohba, T.; Yohena, T.; Osoegawa, A.; Shoji, F.; Maehara, Y. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in nonsmall cell lung cancer. Int. J. Cancer, 2007, 121, 895-900
294. Penning, T.D.; Zhu, G.D.; Gandhi, V.B.; Gong, J.; Liu, X.; Shi, Y.; Klinghofer, V.; Johnson, E.F.; Donawho, C.K.; Frost, D.J.; Bontcheva-Diaz, V.; Bouska, J.J.; Osterling, D.J.; Olson, A.M.; Marsh, K.C.; Luo, Y.; Giranda, V.L. Discovery of the Poly(ADPribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J. Med. Chem., 2009, 52, 514-523
295. Shimizu, J.; Horio, Y.; Osada, H.; Hida, T.; Hasegawa, Y.; Shimokata, K.; Takahashi, T.; Sekido, Y.; Yatabe, Y. mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines. Respirology, 2008, 13, 510-517
296. Perego, P.; Zunino, F.; Carenini, N.; Giuliani, F.; Spinelli, S.; Howell, S.B. Sensitivity to cisplatin and platinum-containing compounds of Schizosaccharomyces pombe rad mutants. Mol. Pharmacol., 1998, 54, 213-219
297. Donawho, C.K.; Luo, Y.; Luo, Y.; Penning, T.D.; Bauch, J.L.; Bouska, J.J.; Bontcheva-Diaz, V.D.; Cox, B.F.; DeWeese, T.L.; Dillehay, L.E.; Ferguson, D.C.; Ghoreishi-Haack, N.S.; Grimm, D.R.; Guan, R.; Han, E.K.; Holley-Shanks, R.R.; Hristov, B.; Idler, K.B.; Jarvis, K.; Johnson, E.F.; Kleinberg, L.R.; Klinghofer, V.; Lasko, L.M.; Liu, X.; Marsh, K.C.; McGonigal, T.P.; Meulbroek, J.A.; Olson, A.M.; Palma, J.P.; Rodriguez, L.E.; Shi, Y.; Stavropoulos, J.A.; Tsurutani, A.C.; Zhu, G.D.; Rosenberg, S.H.; Giranda, V.L.; Frost, D.J. ABT-888, an orally active poly(ADP-ribose) po lymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res., 2007, 13, 2728-2737
298. Amrein, L.; Loignon, M.; Goulet, A.C.; Dunn, M.; Jean-Claude, B.; Aloyz, R.; Panasci, L. Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair via inhibition of DNA-dependent protein kinase. J. Pharmacol. Exp. Ther., 2007, 321, 848-855
299. Christodoulopoulos, G.; Muller, C.; Salles, B.; Kazmi, R.; Panasci, L. Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using wortmannin. Cancer Res., 1998, 58, 1789-1792
300. Belenkov, A.I.; Paiement, J.P.; Panasci, L.C.; Monia, B.P.; Chow, T.Y. An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents. Cancer Res., 2002, 62, 5888-5896
301. Allan, J.M.; Engelward, B.P.; Dreslin, A.J.; Wyatt, M.D.; Tomasz, M.; Samson, L.D. Mammalian 3-methyladenine DNA glycosylase protects against the toxicity and clastogenicity of certain chemotherapeutic DNA cross-linking agents. Cancer Res., 1998, 58, 3965-3973
302. McHugh, P.J.; Sones, W.R.; Hartley, J.A. Repair of intermediate structures produced at DNA interstrand cross-links in Saccharomyces cerevisiae. Mol. Cell Biol., 2000, 20, 3425-3433
303. Barber, L.J.; Ward, T.A.; Hartley, J.A.; McHugh, P.J. DNA interstrand cross-link repair in the Saccharomyces cerevisiae cell cycle: overlapping roles for PSO2 (SNM1) with MutS factors and EXO1 during S phase. Mol. Cell Biol., 2005, 25, 2297-2309
304. McHugh, P.J.; Gill, R.D.; Waters, R.; Hartley, J.A. Excision repair of nitrogen mustard-DNA adducts in Saccharomyces cerevisiae. Nucleic Acids Res., 1999, 27, 3259-3266
305. Kisby, G.E.; Olivas, A.; Park, T.; Churchwell, M.; Doerge, D.; Samson, L.D.; Gerson, S.L.; Turker, M.S. DNA repair modulates the vulnerability of the developing brain to alkylating agents. DNA Repair (Amst)., 2009, 8, 400-412
306. Weltin, D.; Marchal, J.; Dufour, P.; Potworowski, E.; Oth, D.; Bischoff, P. Effect of 6(5H)-phenanthridinone, an inhibitor of poly(ADP-ribose)polymerase, on cultured tumor cells. Oncol. Res., 1994, 6, 399-403
307. Fiumicino, S.; Martinelli, S.; Colussi, C.; Aquilina, G.; Leonetti, C.; Crescenzi, M.; Bignami, M. Sensitivity to DNA cross-linking chemotherapeutic agents in mismatch repair-defective cells in vitro and in xenografts. Int. J. Cancer, 2000, 85, 590-596
308. Aquilina, G.; Crescenzi, M.; Bignami, M. Mismatch repair, G(2)/M cell cycle arrest and lethality after DNA damage. Carcinogenesis, 1999, 20, 2317-2326
309. Ferguson, L.R. Mutagenic and recombinogenic consequences of DNA-repair inhibition during treatment with 1, 3-bis(2-chloroethyl)-1-nitrosourea in Saccharomyces cerevisiae. Mutat. Res., 1990, 241, 369-377
310. Engelward, B.P.; Dreslin, A.; Christensen, J.; Huszar, D.; Kurahara, C.; Samson, L. Repair-deficient 3-methyladenine DNA glycosylase homozygous mutant mouse cells have increased sensitivity to alkylation-induced chromosome damage and cell killing. EMBO J., 1996, 15, 945-952
311. Elder, R.H.; Jansen, J.G.; Weeks, R.J.; Willington, M.A.; Deans, B.; Watson, A.J.; Mynett, K.J.; Bailey, J.A.; Cooper, D.P.; Rafferty, J.A.; Heeran, M.C.; Wijnhoven, S.W.; van Zeeland, A.A.; Margison, G.P. Alkylpurine-DNA-N-glycosylase knockout mice show increased susceptibility to induction of mutations by methyl methanesulfonate. Mol. Cell Biol., 1998, 18, 5828-5837
312. Liu, L.; Markowitz, S.; Gerson, S.L. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res., 1996, 56, 5375-5379
313. Hickman, M.J.; Samson, L.D. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc. Natl. Acad. Sci. U.S.A., 1999, 96, 10764-10769
314. Ono, Y.; Matsumoto, K.; Furuta, T.; Ohmoto, T.; Akiyama, K.; Seki, S. Relationship between expression of a major apurinic/apyrimidinic endonuclease (APEX nuclease) and susceptibility to genotoxic agents in human glioma cell lines. J. Neurooncol., 1995, 25, 183-192
315. Nikolova, T.; Christmann, M.; Kaina, B. FEN1 is overexpressed in testis, lung and brain tumors. Anticancer Res., 2009, 29, 2453-2459
316. Cardinal, J.W.; Margison, G.P.; Mynett, K.J.; Yates, A.P.; Cameron, D.P.; Elder, R.H. Increased susceptibility to streptozotocininduced beta-cell apoptosis and delayed autoimmune diabetes in alkylpurine-DNA-N-glycosylase-deficient mice. Mol. Cell Biol., 2001, 21, 5605-5613
317. Masutani, M.; Suzuki, H.; Kamada, N.; Watanabe, M.; Ueda, O.; Nozaki, T.; Jishage, K.; Watanabe, T.; Sugimoto, T.; Nakagama, H.; Ochiya, T.; Sugimura, T. Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes. Proc. Natl. Acad. Sci. U.S.A., 1999, 96, 2301-2304
318. Kobune, M.; Xu, Y.; Baum, C.; Kelley, M.R.; Williams, D.A. Retrovirus-mediated expression of the base excision repair proteins, formamidopyrimidine DNA glycosylase or human oxoguanine DNA glycosylase, protects hematopoietic cells from N,N',N"-triethylenethiophosphoramide (thioTEPA)-induced toxicity in vitro and in vivo. Cancer Res., 2001, 61, 5116-5125
319. McManus, F.P.; Fang, Q.; Booth, J.D.; Noronha, A.M.; Pegg, A.E.; Wilds, C.J. Synthesis and characterization of an O(6)-2'-deoxyguanosine-Alkyl-O(6)-2'-deoxyguanosine interstrand crosslink in a 5'-GNC motif and repair by human O(6)-Alkylguanine-DNA alkyltransferase. Org. Biomol. Chem., 2010, 8, 4414-4426
320. Yang, S.; Irani, K.; Heffron, S.E.; Jurnak, F.; Meyskens, F.L., Jr. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol. Cancer Ther., 2005, 4, 1923-1935
321. Khan, O.A.; Gore, M.; Lorigan, P.; Stone, J.; Greystoke, A.; Burke, W.; Carmichael, J.; Watson, A.J.; McGown, G.; Thorncroft, M.; Margison, G.P.; Califano, R.; Larkin, J.; Wellman, S.; Middleton, M.R. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br. J. Cancer, 2011, 104, 750-755
322. Schold, S.C., Jr.; Brent, T.P.; von Hofe, E.; Friedman, H.S.; Mitra, S.; Bigner, D.D.; Swenberg, J.A.; Kleihues, P. O6-Alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. J. Neurosurg., 1989, 70, 573-577
323. Mirzoeva, O.K.; Kawaguchi, T.; Pieper, R.O. The Mre11/Rad50/ Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity. Mol. Cancer Ther., 2006, 5, 2757-2766
324. Kondo, N.; Takahashi, A.; Mori, E.; Ohnishi, K.; McKinnon, P.J.; Sakaki, T.; Nakase, H.; Ohnishi, T. DNA ligase IV as a new molecular target for temozolomide Biochem. Biophys. Res. Commun., 2009, 387, 656-660
325. Trivedi, R.N.; Almeida, K.H.; Fornsaglio, J.L.; Schamus, S.; Sobol, R.W. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res., 2005, 65, 6394-6400
326. Du, L.Q.; Du, X.Q.; Bai, J.Q.; Wang, Y.; Yang, Q.S.; Wang, X.C.; Zhao, P.; Wang, H.; Liu, Q.; Fan, F.Y. Methotrexate-mediated inhibition of RAD51 expression and homologous recombination in cancer cells. J. Cancer Res. Clin. Oncol., 2012, 138, 811-818
327. Martin, S.A.; McCarthy, A.; Barber, L.J.; Burgess, D.J.; Parry, S.; Lord, C.J.; Ashworth, A. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol. Med., 2009, 1, 323-337
328. Li, L.; Connor, E.E.; Berger, S.H.; Wyatt, M.D. Determination of apoptosis, uracil incorporation, DNA strand breaks, and sister chromatid exchanges under conditions of thymidylate deprivation in a model of BER deficiency. Biochem. Pharmacol., 2005, 70, 1458-1468
329. Li, L.; Berger, S.H.; Wyatt, M.D. Involvement of base excision repair in response to therapy targeted at thymidylate synthase. Mol. Cancer Ther., 2004, 3, 747-753
330. Luo, Y.; Walla, M.; Wyatt, M.D. Uracil incorporation into genomic DNA does not predict toxicity caused by chemotherapeutic inhibition of thymidylate synthase. DNA Repair (Amst)., 2008, 7, 162-169
331. Welsh, S.J.; Hobbs, S.; Aherne, G.W. Expression of uracil DNA glycosylase (UDG) does not affect cellular sensitivity to thymidylate synthase (TS) inhibition. Eur. J. Cancer, 2003, 39, 378-387
332. Meyers, M.; Wagner, M.W.; Mazurek, A.; Schmutte, C.; Fishel, R.; Boothman, D.A. DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J. Biol. Chem., 2005, 280, 5516-5526
333. Bulgar, A.D.; Weeks, L.D.; Miao, Y.; Yang, S.; Xu, Y.; Guo, C.; Markowitz, S.; Oleinick, N.; Gerson, S.L.; Liu, L. Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair. Cell Death. Dis., 2012, 3, e252
334. Matuo, R.; Sousa, F.G.; Escargueil, A.E.; Soares, D.G.; Grivicich, I.; Saffi, J.; Larsen, A.K.; Henriques, J.A. DNA repair pathways involved in repair of lesions induced by 5-fluorouracil and its active metabolite FdUMP. Biochem. Pharmacol., 2010, 79, 147-153
335. El Awady, R.A.; Saleh, E.M.; Dahm-Daphi, J. Targeting DNA double-strand break repair: is it the right way for sensitizing cells to 5-fluorouracil? Anticancer Drugs, 2010, 21, 277-287
336. Geng, L.; Huehls, A.M.; Wagner, J.M.; Huntoon, C.J.; Karnitz, L.M. Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil. PLoS. One, 2011, 6, e28862
337. Huehls, A.M.; Wagner, J.M.; Huntoon, C.J.; Geng, L.; Erlichman, C.; Patel, A.G.; Kaufmann, S.H.; Karnitz, L.M. Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells. Cancer Res., 2011, 71, 4944-4954
338. Andersen, S.; Heine, T.; Sneve, R.; Konig, I.; Krokan, H.E.; Epe, B.; Nilsen, H. Incorporation of dUMP into DNA is a major source of spontaneous DNA damage, while excision of uracil is not required for cytotoxicity of fluoropyrimidines in mouse embryonic fibroblasts. Carcinogenesis, 2005, 26, 547-555
339. Murakami, J.; Lee, Y.J.; Kokeguchi, S.; Tsujigiwa, H.; Asaumi, J.; Nagatsuka, H.; Fukui, K.; Kuroda, M.; Tanaka, N.; Matsubara, N. Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines. Oncol. Rep., 2007, 17, 1461-1467
340. Terashima, I.; Kohda, K. Cytotoxicity of fluoroethylating agents is potentiated by O6-benzylguanine. Biol. Pharm. Bull., 1996, 19, 956-961
341. Garcia-Diaz, M.; Murray, M.S.; Kunkel, T.A.; Chou, K.M. Interaction between DNA Polymerase lambda and anticancer nucleoside analogs. J. Biol. Chem., 2010, 285, 16874-16879
342. Gaymes, T.J.; Shall, S.; MacPherson, L.J.; Twine, N.A.; Lea, N.C.; Farzaneh, F.; Mufti, G.J. Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. Haematologica, 2009, 94, 638-646
343. van Putten, J.W.G.; Groen, H.J.M.; Smid, K.; Peters, G.J.; Kampinga, H.H. End-joining deficiency and radiosensitization induced by gemcitabine. Cancer Res., 2001, 61, 1585-1591
344. Konduri, S.D.; Ticku, J.; Bobustuc, G.C.; Sutphin, R.M.; Colon, J.; Isley, B.; Bhakat, K.K.; Srivenugopal, K.S.; Baker, C.H. Blockade of MGMT expression by O6 benzyl guanine leads to inhibition of pancreatic cancer growth and induction of apoptosis. Clin. Cancer Res., 2009, 15, 6087-6095
345. Ma, J.; Murphy, M.; O'Dwyer, P.J.; Berman, E.; Reed, K.; Gallo, J.M. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-Acquired resistance. Biochem. Pharmacol., 2002, 63, 1219-1228
346. Moses, K.; Willmore, E.; Harris, A.L.; Durkacz, B.W. Correlation of enhanced 6-mercaptopurine cytotoxicity with increased phosphoribosylpyrophosphate levels in Chinese hamster ovary cells treated with 3-Aminobenzamide. Cancer Res., 1990, 50, 1992-1996
347. Frazelle, J.H.; Harris, J.S.; Swift, M. Responses of Fanconi anemia fibroblasts to adenine and purine analogues. Mutat. Res., 1981, 80, 373-380
348. Lawrenzi, J.; Bunnell, A.; Hentosh, P. Nucleotide excision repairdeficient human cells in culture exhibit decreased survival after 2-chlorodeoxyadenosine treatment. Anticancer Res., 2003, 23, 3141-3145
349. Wang, X.W.; Tseng, A.; Ellis, N.A.; Spillare, E.A.; Linke, S.P.; Robles, A.I.; Seker, H.; Yang, Q.; Hu, P.; Beresten, S.; Bemmels, N.A.; Garfield, S.; Harris, C.C. Functional interaction of p53 and BLM DNA helicase in apoptosis. J. Biol. Chem., 2001, 276, 32948-32955
350. Zhang, Z.Z.; Zhang, Q.; Wu, M. Constructing the eukaryotic expression vector to study preliminarily the functions of hammerhead ribozyme targeting base excision repair gene HOGG1 Sichuan. Da. Xue. Xue. Bao. Yi. Xue. Ban., 2006, 37, 165-170
351. Liu, S.; Wu, M.; Zhang, Z. Involvement of DNA polymerase beta in repairing oxidative damages induced by antitumor drug adriamycin. Toxicol. Appl. Pharmacol., 2010, 246(3), 163-170
352. Andera, L.; Wasylyk, B. Transcription abnormalities potentiate apoptosis of normal human fibroblasts. Mol. Med., 1997, 3, 852-863
353. Kamisugi, Y.; Schaefer, D.G.; Kozak, J.; Charlot, F.; Vrielynck, N.; Hola, M.; Angelis, K.J.; Cuming, A.C.; Nogue, F. MRE11 and RAD50, but not NBS1, are essential for gene targeting in the moss Physcomitrella patens. Nucleic Acids Res., 2012, 40, 3496-3510
354. Garcia-Prieto, F.; Gomez-Raja, J.; Andaluz, E.; Calderone, R.; Larriba, G. Role of the homologous recombination genes RAD51 and RAD59 in the resistance of Candida albicans to UV light, radiomimetic and anti-tumor compounds and oxidizing agents. Fungal. Genet. Biol., 2010, 47, 433-445
355. He, Y.H.; Wu, M.; Kobune, M.; Xu, Y.; Kelley, M.R.; Martin, W.J. Expression of yeast apurinic/apyrimidinic endonuclease (APN1) protects lung epithelial cells from bleomycin toxicity. Am. J. Respir. Cell Mol. Biol., 2001, 25, 692-698
356. Fisher, L.A.; Samson, L.; Bessho, T. Removal of reactive oxygen species-induced 3'-blocked ends by XPF-ERCC1. Chem. Res. Toxicol., 2011, 24, 1876-1881
357. Maki, Y.; Murakami, J.; Asaumi, J.; Tsujigiwa, H.; Nagatsuka, H.; Kokeguchi, S.; Fukui, K.; Kawai, N.; Yanagi, Y.; Kuroda, M.; Tanaka, N.; Matsubara, N.; Kishi, K. Role of O6-methylguanine-DNA methyltransferase and effect of O6-benzylguanine on the anti-tumor activity of cis-diaminedichloroplatinum(II) in oral cancer cell lines. Oral Oncol., 2005, 41, 984-993
358. Keszenman, D.J.; Candreva, E.C.; Sanchez, A.G.; Nunes, E. RAD6 gene is involved in heat shock induction of bleomycin resistance in Saccharomyces cerevisiae. Environ. Mol. Mutagen., 2005, 45, 36-43
359. Honma, M.; Tadokoro, S.; Sakamoto, H.; Tanabe, H.; Sugimoto, M.; Furuichi, Y.; Satoh, T.; Sofuni, T.; Goto, M.; Hayashi, M. Chromosomal instability in B-lymphoblasotoid cell lines from Werner and Bloom syndrome patients. Mutat. Res., 2002, 520, 15-24
360. Kim, Y.C.; Koh, J.T.; Shin, B.A.; Ahn, K.Y.; Choi, B.K.; Kim, C.G.; Kim, K.K. An antisense construct of full-length human RAD50 cDNA confers sensitivity to ionizing radiation and alkylating agents on human cell lines. Radiat. Res., 2002, 157, 19-25
361. Pluth, J.M.; Fried, L.M.; Kirchgessner, C.U. Severe combined immunodeficient cells expressing mutant hRAD54 exhibit a marked DNA double-strand break repair and error-prone chromosome repair defect. Cancer Res., 2001, 61, 2649-2655
362. Ramotar, D.; Popoff, S.C.; Gralla, E.B.; Demple, B. Cellular role of yeast Apn1 apurinic endonuclease/3'-diesterase: repair of oxidative and alkylation DNA damage and control of spontaneous mutation. Mol. Cell Biol., 1991, 11, 4537-4544
363. Capp, J.P.; Boudsocq, F.; Bertrand, P.; Laroche-Clary, A.; Pourquier, P.; Lopez, B.S.; Cazaux, C.; Hoffmann, J.S.; Canitrot, Y. The DNA polymerase lambda is required for the repair of noncompatible DNA double strand breaks by NHEJ in mammalian cells. Nucleic Acids Res., 2006, 34, 2998-3007
364. Shen, M.R.; Zdzienicka, M.Z.; Mohrenweiser, H.; Thompson, L.H.; Thelen, M.P. Mutations in hamster single-strand break repair gene XRCC1 causing defective DNA repair. Nucleic Acids Res., 1998, 26, 1032-1037
365. Minko, I.G.; Harbut, M.B.; Kozekov, I.D.; Kozekova, A.; Jakobs, P.M.; Olson, S.B.; Moses, R.E.; Harris, T.M.; Rizzo, C.J.; Lloyd, R.S. Role for DNA polymerase kappa in the processing of N2-N2-guanine interstrand cross-links. J. Biol. Chem., 2008, 283, 17075-17082
366. Wang, W.; Seki, M.; Narita, Y.; Sonoda, E.; Takeda, S.; Yamada, K.; Masuko, T.; Katada, T.; Enomoto, T. Possible association of BLM in decreasing DNA double strand breaks during DNA replication. EMBO J., 2000, 19, 3428-3435
367. Malik, M.; Nitiss, J.L. DNA repair functions that control sensitivity to topoisomerase-targeting drugs. Eukaryot. Cell., 2004, 3, 82-90
368. Liu, C.; Pouliot, J.J.; Nash, H.A. Repair of topoisomerase I covalent complexes in the absence of the tyrosyl-DNA phosphodiesterase Tdp1. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 14970-14975
369. Benton, M.G.; Glasser, N.R.; Palecek, S.P. Deletion of MAG1 and MRE11 enhances the sensitivity of the Saccharomyces cerevisiae HUG1P-GFP promoter-reporter construct to genotoxicity. Biosens. Bioelectron., 2008, 24, 736-741
370. Adachi, N.; So, S.; Koyama, H. Loss of nonhomologous end joining confers camptothecin resistance in DT40 cells. Implications for the repair of topoisomerase I-mediated DNA damage. J. Biol. Chem., 2004, 279, 37343-37348
371. Zheng, L.; Zhou, M.; Chai, Q.; Parrish, J.; Xue, D.; Patrick, S.M.; Turchi, J.J.; Yannone, S.M.; Chen, D.; Shen, B. Novel function of the flap endonuclease 1 complex in processing stalled DNA replication forks. EMBO Rep., 2005, 6, 83-89
372. Squires, S.; Ryan, A.J.; Strutt, H.L.; Johnson, R.T. Hypersensitivity of Cockayne's syndrome cells to camptothecin is associated with the generation of abnormally high levels of double strand breaks in nascent DNA. Cancer Res., 1993, 53, 2012-2019
373. Kerzendorfer, C.; Whibley, A.; Carpenter, G.; Outwin, E.; Chiang, S.C.; Turner, G.; Schwartz, C.; El Khamisy, S.; Raymond, F.L.; O'Driscoll, M. Mutations in Cullin 4B result in a human syndrome associated with increased camptothecin-induced topoisomerase Idependent DNA breaks. Hum. Mol. Genet., 2010, 19, 1324-1334
374. Jacob, S.; Aguado, M.; Fallik, D.; Praz, F. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res., 2001, 61, 6555-6562
375. Pichierri, P.; Franchitto, A.; Piergentili, R.; Colussi, C.; Palitti, F. Hypersensitivity to camptothecin in MSH2 deficient cells is correlated with a role for MSH2 protein in recombinational repair. Carcinogenesis, 2001, 22, 1781-1787
376. Ochi, Y.; Sugawara, H.; Iwami, M.; Tanaka, M.; Eki, T. Sensitive detection of chemical-induced genotoxicity by the Cypridina secretory luciferase reporter assay, using DNA repair-deficient strains of Saccharomyces cerevisiae. Yeast, 2011, 28, 265-278
377. Kuo, C.C.; Liu, J.F.; Chang, J.Y. DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors. J. Pharmacol. Exp. Ther., 2006, 316, 946-954
378. Yoshimura, A.; Nishino, K.; Takezawa, J.; Tada, S.; Kobayashi, T.; Sonoda, E.; Kawamoto, T.; Takeda, S.; Ishii, Y.; Yamada, K.; Enomoto, T.; Seki, M. A novel Rad18 function involved in protection of the vertebrate genome after exposure to camptothecin. DNA Repair (Amst)., 2006, 5, 1307-1316
379. Scheller, J.; Schurer, A.; Rudolph, C.; Hettwer, S.; Kramer, W. MPH1, a yeast gene encoding a DEAH protein, plays a role in protection of the genome from spontaneous and chemically induced damage. Genetics, 2000, 155, 1069-1081
380. Shiomi, N.; Mori, M.; Tsuji, H.; Imai, T.; Inoue, H.; Tateishi, S.; Yamaizumi, M.; Shiomi, T. Human RAD18 is involved in S phasespecific single-strand break repair without PCNA monoubiquitination. Nucleic Acids Res., 2007, 35, e9
381. Magrini, R.; Bhonde, M.R.; Hanski, M.L.; Notter, M.; Scherubl, H.; Boland, C.R.; Zeitz, M.; Hanski, C. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int. J. Cancer, 2002, 101, 23-31
382. Cai, W.; Maldonado, N.V.; Cui, W.; Harutyunyan, N.; Ji, L.; Sposto, R.; Reynolds, C.P.; Keshelava, N. Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models. Br. J. Cancer, 2010, 103, 1369-1379
383. Hamilton, N.K.; Maizels, N. MRE11 function in response to topoisomerase poisons is independent of its function in double-strand break repair in Saccharomyces cerevisiae. PLoS One, 2010, 5, e15387
384. Biard, D.S. Untangling the relationships between DNA repair pathways by silencing more than 20 DNA repair genes in human stable clones. Nucleic Acids Res., 2007, 35, 3535-3550
385. Sengupta, S.; Mantha, A.K.; Mitra, S.; Bhakat, K.K. Human AP endonuclease (APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II loading in the drug-induced activation of multidrug resistance gene MDR1. Oncogene, 2011, 30, 482-493
386. Matsuzaki, Y.; Adachi, N.; Koyama, H. Vertebrate cells lacking FEN-1 endonuclease are viable but hypersensitive to methylating agents and H2O2. Nucleic Acids Res., 2002, 30, 3273-3277
387. Canitrot, Y.; de Murcia, G.; Salles, B. Decreased expression of topoisomerase IIbeta in poly(ADP-ribose) polymerase-deficient cells. Nucleic Acids Res., 1998, 26, 5134-5138
388. Lawson, M.H.; Cummings, N.M.; Rassl, D.M.; Russell, R.; Brenton, J.D.; Rintoul, R.C.; Murphy, G. Two novel determinants of etoposide resistance in small cell lung cancer. Cancer Res., 2011, 71, 4877-4887
389. Tsai, M.S.; Weng, S.H.; Chen, H.J.; Chiu, Y.F.; Huang, Y.C.; Tseng, S.C.; Kuo, Y.H.; Lin, Y.W. Inhibition of p38 MAPKdependent excision repair cross-complementing 1 expression decreases the DNA repair capacity to sensitize lung cancer cells to etoposide. Mol. Cancer Ther., 2012, 11, 561-571
390. Despras, E.; Pfeiffer, P.; Salles, B.; Calsou, P.; Kuhfittig-Kulle, S.; Angulo, J.F.; Biard, D.S. Long-term XPC silencing reduces DNA double-strand break repair. Cancer Res., 2007, 67, 2526-2534
391. Winter, S.; Weller, M. Poly(ADP-ribose) polymerase-independent potentiation of nitrosourea cytotoxicity by 3-Aminobenzamide in human malignant glioma cells. Eur. J. Pharmacol., 2000, 398, 177-183
392. Lafarge, S.; Sylvain, V.; Ferrara, M.; Bignon, Y.J. Inhibition of BRCA1 leads to increased chemoresistance to microtubuleinterfering agents, an effect that involves the JNK pathway. Oncogene, 2001, 20, 6597-6606
393. Chen, H.; Shao, C.; Shi, H.; Mu, Y.; Sai, K.; Chen, Z. Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 visa-vis chemotherapy drug cytotoxicity in human glioma. J. Neurooncol., 2007, 82, 257-262
394. Richardson, D.S.; Allen, P.D.; Kelsey, S.M.; Newland, A.C. Effects of PARP inhibition on drug and Fas-induced apoptosis in leukaemic cells. Adv. Exp. Med. Biol., 1999, 457, 267-279
395. Moisan, F.; Laroche-Clary, A.; Auzanneau, C.; Ricard, N.; Pourquier, P.; Robert, J.; Le, M., V Deciphering the role of the ERCC2 gene polymorphism on anticancer drug sensitivity. Carcinogenesis, 2012, 33, 962-968
396. Yang, J.J.; Bhojwani, D.; Yang, W.; Cai, X.; Stocco, G.; Crews, K.; Wang, J.; Morrison, D.; Devidas, M.; Hunger, S.P.; Willman, C.L.; Raetz, E.A.; Pui, C.H.; Evans, W.E.; Relling, M.V.; Carroll, W.L. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood, 2008, 112, 4178-4183
397. Srinivas, G.; Annab, L.A.; Gopinath, G.; Banerji, A.; Srinivas, P. Antisense blocking of BRCA1 enhances sensitivity to plumbagin but not tamoxifen in BG-1 ovarian cancer cells. Mol. Carcinog., 2004, 39, 15-25
398. Chahal, M.; Xu, Y.; Lesniak, D.; Graham, K.; Famulski, K.; Christensen, J.G.; Aghi, M.; Jacques, A.; Murray, D.; Sabri, S.; Abdulkarim, B. MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro. Oncol., 2010, 12, 822-833
399. Ko, J.C.; Hong, J.H.; Wang, L.H.; Lin, Y.W. The role of repair protein Rad51 in synergistic cytotoxicity and mutagenicity induced by epidermal growth factor receptor inhibitor (Gefitinib, IressaR) and benzo[a]pyrene in human lung cancer. Exp. Cell Res., 2008, 314, 1881-1891
400. Ko, J.C.; Hong, J.H.; Wang, L.H.; Cheng, C.M.; Ciou, S.C.; Lin, S.T.; Jheng, M.Y.; Lin, Y.W. Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells. Mol. Cancer Ther., 2008, 7, 3632-3641
401. Chen, R.S.; Jhan, J.Y.; Su, Y.J.; Lee, W.T.; Cheng, C.M.; Ciou, S.C.; Lin, S.T.; Chuang, S.M.; Ko, J.C.; Lin, Y.W. Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation. Exp. Cell Res., 2009, 315, 2658-2672
402. Huang, Y.; Rachid, Z.; Jean-Claude, B.J. MGMT is a molecular determinant for potency of the DNA-EGFR-combi-molecule ZRS1. Mol. Cancer Res., 2011, 9, 320-331
403. Moehring, A.; Wohlbold, L.; Aulitzky, W.E.; van der, K.H. Role of poly(ADP-ribose) polymerase activity in imatinib mesylateinduced cell death. Cell Death Differ., 2005, 12, 627-636
404. Ababou, M.; Dumaire, V.; Lecluse, Y.; Amor-Gueret, M. Cleavage of BLM and sensitivity of Bloom's syndrome cells to hydroxurea and UV-C radiation. Cell Cycle, 2002, 1, 262-266
405. Lewis, L.K.; Storici, F.; Van Komen, S.; Calero, S.; Sung, P.; Resnick, M.A. Role of the nuclease activity of Saccharomyces cerevisiae Mre11 in repair of DNA double-strand breaks in mitotic cells. Genetics, 2004, 166, 1701-1713
406. Hartsuiker, E.; Vaessen, E.; Carr, A.M.; Kohli, J. Fission yeast Rad50 stimulates sister chromatid recombination and links cohesion with repair. EMBO J., 2001, 20, 6660-6671
407. de Vries, F.A.; Zonneveld, J.B.; Duijn-Goedhart, A.; Roodbergen, M.; Boei, J.; van Buul, P.P.; Essers, J.; van Steeg, H.; van Zeeland, A.A.; van Benthem, J.; Pastink, A. Inactivation of RAD52 aggra vates RAD54 defects in mice but not in Schizosaccharomyces pombe. DNA Repair (Amst)., 2005, 4, 1121-1128
408. Ninomiya, Y.; Suzuki, K.; Ishii, C.; Inoue, H. Highly efficient gene replacements in Neurospora strains deficient for nonhomologous end-joining. Proc. Natl. Acad. Sci. U.S.A., 2004, 101, 12248-12253
409. Miyoshi, T.; Sadaie, M.; Kanoh, J.; Ishikawa, F. Telomeric DNA ends are essential for the localization of Ku at telomeres in fission yeast. J. Biol. Chem., 2003, 278, 1924-1931
410. Elder, R.T.; Song, X.Q.; Chen, M.; Hopkins, K.M.; Lieberman, H.B.; Zhao, Y. Involvement of rhp23, a Schizosaccharomyces pombe homolog of the human HHR23A and Saccharomyces cerevisiae RAD23 nucleotide excision repair genes, in cell cycle control and protein ubiquitination. Nucleic Acids Res., 2002, 30, 581-591
411. Suhasini, A.N.; Rawtani, N.A.; Wu, Y.; Sommers, J.A.; Sharma, S.; Mosedale, G.; North, P.S.; Cantor, S.B.; Hickson, I.D.; Brosh, R.M., Jr. Interaction between the helicases genetically linked to Fanconi anemia group J and Bloom's syndrome. EMBO J., 2011, 30, 692-705
412. Kats, E.S.; Enserink, J.M.; Martinez, S.; Kolodner, R.D. The Saccharomyces cerevisiae Rad6 postreplication repair and Siz1/Srs2 homologous recombination-inhibiting pathways process DNA damage that arises in asf1 mutants. Mol. Cell Biol., 2009, 29, 5226-5237
413. Bi, X.; Barkley, L.R.; Slater, D.M.; Tateishi, S.; Yamaizumi, M.; Ohmori, H.; Vaziri, C. Rad18 regulates DNA polymerase kappa and is required for recovery from S-phase checkpoint-mediated arrest. Mol. Cell Biol., 2006, 26, 3527-3540
414. Herrero, A.B.; Martin-Castellanos, C.; Marco, E.; Gago, F.; Moreno, S. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res., 2006, 66, 8155-8162
415. Soares, D.G.; Poletto, N.P.; Bonatto, D.; Salvador, M.; Schwartsmann, G.; Henriques, J.A. Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways. Biochem. Pharmacol., 2005, 70, 59-69
416. Orta, M.L.; Calderón-Montaño, J.M.; Domínguez, I.; Pastor, N.; Burgos-Morón, E.; López-Lázaro, M.; Cortés, F.; Mateos, S.; Helleday, T. 5-Aza-2'-deoxycytidine causes replication lesions that require Fanconi anemia-dependent homologous recombination for repair. Nucleic Acids Res., 2013, 41, 5827-5836